

CITATION REPORT

List of articles citing

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

DOI: 10.1093/jnci/92.3.205

Journal of the National Cancer Institute, 2000, 92, 205-16.

Source: <https://exaly.com/paper-pdf/32226668/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2251	International Journal of Oncology.		56
2250	Image-guided Ablation in the Thorax. 440-474		2
2249	Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. 2010 , 4, 178		12
2248	Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours. 2012 , 6, 280		2
2247	Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. 2015 , 47, 72-7		14
2246	Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD2 antibody in adoptive immunotherapy of cancer. 1992 , 34, 563		2
2245	http://www.spandidos-publications.com/ijo/article.jsp?article_id=ijo_33_3_541 . 1992 , 33, 549		
2244	An integrative genomic and proteomic approach to chemosensitivity prediction. 2009 , 34, 107-15		12
2243	Maintenance immunotherapy in metastatic breast cancer. 1994 , 20, 1173		3
2242	EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. 1994 , 21, 413		4
2241	Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: A Phase III study. 1994 , 20, 879		
2240	Mitochondrial ultrastructure-associated chemotherapy response in ovarian cancer. 1994 , 21, 199		
2239	Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. 1994 , 20, 1305		
2238	Phase II study of vinorelbine in patients with malignant pleural mesothelioma. 2000 , 18, 3912-7		170
2237	Cancer imaging - the significance of the findings. 2000 , 1, 28-34		
2236	Chemotherapy and Angiogenesis in Advanced Cancer: Vascular Endothelial Growth Factor (VEGF) Decline as Predictor of Disease Control during Taxol Therapy in Metastatic Breast Cancer. 2000 , 15, 308-311		25
2235	Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design. 2000 , 34, 83-8		20

2234	Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. 2000 , 3, 128-133		23
2233	Introduction. 2000 , 86, 3-3		
2232	Do We Have Good Surrogate Endpoints for Survival in Breast Cancer Studies?. 2000 , 86, 4-10		
2231	CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. 2000 , 73, 1178-84		114
2230	Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 179-81	9.7	108
2229	Commentary. Are current tumour response criteria relevant for the 21st century?. 2000 , 73, 1031-3		30
2228	Changes in findings of mammography, ultrasonography and contrast-enhanced computed tomography of three histological complete responders with primary breast cancer before and after neoadjuvant chemotherapy: case reports. 2000 , 30, 453-7		10
2227	Clinical imaging of cancer metastasis. 2000 , 36, 1661-70		28
2226	Therapeutic studies. 2000 , 14, 849-76, ix		5
2225	Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. 2001 , 3, 183-91		35
2224	Developmental therapeutics in childhood cancer. A perspective from the Children's Oncology Group and the US Food and Drug Administration. 2001 , 15, 631-55		7
2223	Clinical role of positron emission tomography in oncology. 2001 , 2, 157-64		212
2222	Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. 2001 , 358, 1421-3		1091
2221	Tratamiento no quirúrgico de los tumores reos: quimioterapia y radioterapia. 2001 , 34, 1-7		
2220	[Assessment of paclitaxel treatment of non-small-cell lung cancer]. 2001 , 117, 167-71		0
2219	Physiological imaging. 2001 , 265-274		
2218	Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. 2001 , 19, 1071-7		45
2217	Clinical trial designs for cytostatic agents. 2001 , 19, 3154-5		24

2216	Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. 2001 , 19, 4054-7	160
2215	[TNM system and modern diagnostic imaging]. 2001 , 24, 76-80	
2214	Clinical trials in neuro-oncology. 2001 , 14, 689-94	7
2213	Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for residual or recurrent cranial base and cervical chordomas. 2001 , 10, E5	42
2212	The Common Data Element Dictionary - a standard nomenclature for the reporting of Phase 3 cancer clinical trial data.	
2211	The new Japanese classification of gastric carcinoma: revised explanation of "response assessment of chemotherapy and radiotherapy for gastric carcinoma". 2001 , 4, 9-13	6
2210	Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. 2001 , 51, 56-61	95
2209	Remarks and conclusions on ovarian cancer treatment. 2001 , 11 Suppl 1, 77-81	4
2208	Response evaluation criteria in solid tumors (RECIST): new guidelines. 2001 , 37, 1-3	158
2207	CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. 2001 , 66, 249-54	17
2206	Treating liver metastases: let us count the ways. 2001 , 58, 119-125	
2205	Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1401-5	9-7 93
2204	The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. 2001 , 74, 983-6	193
2203	Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors. 2001 , 1, 258-68	3
2202	Concurrent chemoradiotherapy for squamous cell carcinoma of thoracic esophagus: feasibility and outcome of large regional field and high-dose external beam boost irradiation. 2001 , 31, 375-81	11
2201	[The TNM-System and oncologic-radiologic findings]. 2001 , 173, 965-8	1
2200	Radiologic measurement of tumor size in clinical trials: past, present, and future. 2001 , 176, 333-4	45
2199	Clinical trial design for target-based therapy. 2002 , 7, 401-9	127

2198	Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. 2002 , 222, 797-804	104
2197	Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. 2002 , 20, 2537-44	157
2196	Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer. 2002 , 2, 417-25	3
2195	A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. 2002 , 87, 393-9	107
2194	Clinical trial design and scoring of radionuclide therapy endpoints: normal organ toxicity and tumor response. 2002 , 17, 83-99	12
2193	Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer. 2002 , 87, 158-60	16
2192	A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. 2002 , 87, 491-6	189
2191	Novel endpoints and design of early clinical trials. 2002 , 13 Suppl 4, 139-43	45
2190	Evaluation of response: new and standard criteria. 2002 , 13 Suppl 4, 127-9	40
2189	Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: A phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. 2002 , 20, 419	2
2188	Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. 2002 , 20, 1049	2
2187	Differential chemosensitivity in human intracerebral gliomas measured by flow cytometric DNA analysis. 2002 , 10, 187	
2186	O6-Methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. 2002 , 21, 1125	0
2185	Assessment of Cervical Cancer Radioresponse by Serum Squamous Cell Carcinoma Antigen and Magnetic Resonance Imaging. 2002 , 100, 781-787	1
2184	Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. 2002 , 75, 903-8	51
2183	CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. 2002 , 225, 416-9	180
2182	Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. 2002 , 20, 3772-84	222
2181	Randomized discontinuation design: application to cytostatic antineoplastic agents. 2002 , 20, 4478-84	177

2180	Medical Imaging for Improved Tumour Characterization, Delineation and Treatment Verification. 2002 , 41, 604-614		15
2179	Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. 2002 , 13, 721-9		62
2178	Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. 2002 , 35, 1463-8		50
2177	Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. 2002 , 13, 1893-8		95
2176	Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. 2002 , 20, 4508-16		55
2175	Survey of Modalities of Toxicity Assessment and Reporting in Noncomparative Prospective Studies of Chemotherapy in Breast Cancer. 2002 , 20, 52-57		4
2174	Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1484-93	9.7	246
2173	CA125 response: can it replace the traditional response criteria in ovarian cancer?. 2002 , 7, 437-43		71
2172	Challenges and opportunities for in vivo imaging in oncology. 2002 , 1, 419-22		10
2171	Diffusion MRI: A New Strategy for Assessment of Cancer Therapeutic Efficacy. 2002 , 1, 153535002002214		3
2170	Magnetic resonance imaging of the liver: assessing response to treatment. 2002 , 13, 191-200		14
2169	Clinical results using biochemotherapy as a standard of care in advanced melanoma. 2002 , 12, 381-7		7
2168	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. 2002 , 99, 4234-6		176
2167	Dendritic cells as adjuvants in antitumor immune therapy. 2002 , 25, 456-64		10
2166	Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. 2002 , 9, 661		
2165	Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. 2002 , 9, 887		1
2164	ET-743. 2002 , 62, 1185-92; discussion 1193-4		17
2163	Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. 2002 , 131, S128-34		13

2162	Percutaneous transhepatic lymphography method to image and treat intra-abdominal lymph node metastasis in patients with unresectable hepatobiliary pancreatic cancer. 2002 , 131, 529-33	6
2161	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. 2002 , 20, 4292-302	717
2160	Automatic lesion detection and volume measurement in MR imaging of plexiform neurofibromas.	1
2159	Endpoints in prostate cancer clinical trials. 2002 , 60, 101-7; discussion 107-8	17
2158	Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. 2002 , 100, 781-7	47
2157	Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. 2002 , 38, 543-9	350
2156	Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?. 2002 , 38, 635-8	28
2155	Statistical methodology of phase III cancer clinical trials: advances and future perspectives. 2002 , 38 Suppl 4, S162-8	10
2154	Guidelines on endocrine therapy of breast cancer EUSOMA. 2002 , 38, 615-34	49
2153	Functional MRI for anticancer therapy assessment. 2002 , 38, 2116-27	86
2152	Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. 2002 , 38 Suppl 5, S83-7	170
2151	Clinical trial designs for targeted agents. 2002 , 16, 1287-305	12
2150	Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. 2002 , 131, 433-42	81
2149	Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer. 2002 , 20, 52-7	8
2148	Imatinib mesylate, the first molecularly targeted gene suppressor. 2002 , 22, 1249-65	12
2147	Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. 2002 , 29, 97-101	15
2146	Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. 2002 , 24, 32-44	71
2145	The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. 2002 , 42, 570-4; discussion 575-6	40

2144	A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. 2002 , 24, 1054-9	13
2143	The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. 2002 , 95, 1199-205	78
2142	A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. 2002 , 95, 1629-36	111
2141	Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer. 2002 , 9, 153-9	22
2140	Does palliative chemotherapy palliate?. 2002 , 4, 361	
2139	Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. 2002 , 3, 232-8	2
2138	Oncology drug development: United States Food and Drug Administration perspective. 2002 , 42, 137-43	25
2137	Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). 2002 , 42, 145-55	26
2136	Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. 2002 , 12, 250-6	28
2135	Non-surgical treatment of hepatocellular carcinoma. 2002 , 16, 1-15	27
2134	Angiogenesis modulation in cancer research: novel clinical approaches. 2002 , 1, 415-26	144
2133	Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. 2002 , 86, 336-41	20
2132	Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. 2002 , 86, 342-5	130
2131	Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study. 2002 , 87, 1360-4	10
2130	Structural changes induced by antineoplastic therapies: keys to evaluate tumor response to treatment. 2002 , 12, 928-37	1
2129	New trial designs to assess antitumor and antiproliferative agents in prostate cancer. 2002 , 20, 201-8	10
2128	Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. 2002 , 52, 1041-6	254
2127	Surgical and medical therapy for pancreatic carcinoma. 2002 , 16, 435-55	31

2126	A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. 2003 , 21, 103-7	26
2125	Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. 2003 , 21, 359-66	17
2124	Specific keynote: clinical trial design problems in ovarian cancer. 2003 , 88, S117-21; discussion S122-3	1
2123	In vivo imaging of chemotherapy-induced apoptosis in human cancers. 2003 , 1010, 525-9	30
2122	Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. 2003 , 21, 3761-9	37
2121	[Gemcitabine in advanced bladder cancer]. 2003 , 42, 63-77	
2120	Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. 2003 , 10, 38-44	22
2119	Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. 2003 , 52, 125-30	9
2118	A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies. 2003 , 52, 277-81	7
2117	Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemo-naïve advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study. 2003 , 52, 153-8	11
2116	Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. 2003 , 52, 367-70	13
2115	The role of SPET and PET in monitoring tumour response to therapy. 2003 , 30, 1173-200	18
2114	Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1. 2003 , 6 Suppl 1, 24-7	7
2113	A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. 2003 , 6 Suppl 1, 34-9	35
2112	Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. 2003 , 6, 153-8	9
2111	A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. 2003 , 8, 301-4	11
2110	Biweekly paclitaxel in patients with metastatic breast cancer. 2003 , 8, 357-61	2
2109	Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. 2003 , 8, 374-80	31

2108	Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. 2003 , 3, 205-19	22
2107	New frontiers in the treatment of malignant glioma. 2003 , 30, 72-6	15
2106	Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. 2003 , 5, 174-6	10
2105	Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. 2003 , 3, 19	56
2104	Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. 2003 , 88, 266-9	87
2103	Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. 2003 , 97, 758-71	42
2102	Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. 2003 , 98, 1611-9	32
2101	A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. 2003 , 98, 1942-6	71
2100	A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. 2003 , 98, 2592-8	81
2099	Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. 2003 , 55, 1331-40	75
2098	Quality assurance in clinical trials. 2003 , 47, 213-35	23
2097	The potential for prostate cancer immunotherapy. 2003 , 46 Suppl, S117-25	12
2096	Are radiologists meeting the needs of Australian medical oncologists? Results of a national survey. 2003 , 47, 268-73	6
2095	Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma. 2003 , 1, 635-42	3
2094	Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. 2003 , 92, 379-83; discussion 383-4	21
2093	Editorial comment. 2003 , 92, 383-384	2
2092	Merkel cell carcinoma--a retrospective analysis of 17 cases. 2003 , 17, 20-4	23
2091	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. 2003 , 120, 970-7	53

2090	Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. 2003 , 57, 80-92	100
2089	Ovarian cancer treatment: what is new. 2003 , 13 Suppl 2, 241-50	15
2088	Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients. 2003 , 94, 1015-20	66
2087	Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. 2003 , 88, 25-30	45
2086	Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. 2003 , 89, 460-4	107
2085	Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?. 2003 , 89, 457-9	55
2084	Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. 2003 , 89, 1180-4	54
2083	Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. 2003 , 89, 1896-900	23
2082	A phase II irinotecan-cisplatin combination in advanced pancreatic cancer. 2003 , 89, 1860-4	10
2081	Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. 2003 , 31, 1-10	54
2080	Kit expression in small cell carcinomas of the lung: effects of chemotherapy. 2003 , 16, 1041-7	46
2079	Clinical biomarkers in drug discovery and development. 2003 , 2, 566-80	583
2078	Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. 2003 , 57, 90-7	61
2077	Efficacy of irradiation and external hyperthermia in locally advanced, hormone-refractory or radiation recurrent prostate cancer: a preliminary report. 2003 , 57, 654-64	21
2076	Lung nodule detection and characterization with multislice CT. 2003 , 41, 575-97, vi	28
2075	Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. 2003 , 169, 1738-41	24
2074	Clinical evaluation of dynamic arc conformal radiotherapy for paraaortic lymph node metastasis. 2003 , 67, 113-8	8
2073	Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. 2003 , 63, 217-36	56

2072	Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. 2003 , 63, 513-22; discussion 523-4	83
2071	Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. 2003 , 4, 292-4	19
2070	Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy. 2003 , 2, 46-9	11
2069	Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. 2003 , 21, 4016-26	282
2068	Small pulmonary nodules: volume measurement at chest CT--phantom study. 2003 , 228, 864-70	167
2067	Hepatocellular carcinoma: present status and future prospects. 2003 , 38 Suppl 1, S136-49	176
2066	Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). 2003 , 41, 227-31	105
2065	Imaging: conventional techniques or PET scanning?. 2003 , 1, 211-220	
2064	Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. 2003 , 61, 993-8	33
2063	The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). 2003 , 39, 353-7	59
2062	Imatinib mesylate (STI-571 Glivec [®] , Gleevec [®]) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. 2003 , 39, 2006-2011	339
2061	¹⁸ F-FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Gleevec). 2003 , 39, 2012-20	424
2060	Chemotherapy in alveolar soft part sarcomas. What do we know?. 2003 , 39, 1511-6	95
2059	A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. 2003 , 39, 1377-83	18
2058	A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. 2003 , 39, 2328-33	25
2057	Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. 2003 , 39, 2334-40	42
2056	Value of FDG-PET in the management of non-small cell lung cancer. 2003 , 45, 49-59	47
2055	Study of suboptimum treatment response: lessons from breast cancer. 2003 , 4, 177-85	49

2054	Statistical design in phase II clinical trials and its application in breast cancer. 2003 , 4, 305-11	22
2053	Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. 2003 , 5, 86-93	37
2052	[Non-small cell lung cancer. Survival after radiotherapy and prognostic factors]. 2003 , 39, 81-6	1
2051	Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. 2003 , 170, 1141-5	79
2050	Can paediatric radiologists resist RECIST (response evaluation criteria in solid tumours)?. 2003 , 33, 739-43	12
2049	Assessment of organ volume with different techniques using a living liver model. 2003 , 13, 1286-90	18
2048	Estramustine Phosphate Sodium. 2003 , 2, 373-390	4
2047	Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. 2003 , 21, 2094-100	55
2046	Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 2003 , 21, 2889-95	295
2045	New chemotherapy treatments in advanced cancer patients: an easily applicable evaluation of clinical efficacy and cost-effectiveness. 2003 , 42, 895-902	10
2044	End points and United States Food and Drug Administration approval of oncology drugs. 2003 , 21, 1404-11	391
2043	Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. 2003 , 21, 3092-7	116
2042	The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid. 2003 , 13, 577-84	43
2041	Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. 2003 , 17, 339-54	16
2040	Use of CA-125 to assess response to new agents in ovarian cancer trials. 2003 , 21, 187s-193s	166
2039	Volumetry of hepatic metastases in computed tomography using the watershed and active contour algorithms.	16
2038	Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?. 2003 , 21, 3718-20	11
2037	Measuring response in solid tumors: comparison of RECIST and WHO response criteria. 2003 , 33, 533-7	162

2036	The myth of measurable disease in ovarian cancer. 2003 , 21, 3013-5	24
2035	Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. 2003 , 14, 1115-20	82
2034	Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. 2003 , 228, 335-45	336
2033	Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. 2003 , 14, 1378-82	46
2032	Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. 2003 , 21, 123-8	216
2031	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. 2003 , 21, 1980-7	508
2030	Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. 2003 , 21, 2658-63	192
2029	Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. 2003 , 21, 1760-6	158
2028	Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. 2003 , 21, 2574-82	381
2027	Fluoropyrimidines in Cancer Therapy. 2003 ,	4
2026	Reproducibility of the assessment of tumor extent in the breast using multiple image modalities. 2003 , 30, 2919-26	16
2025	Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). 2003 , 88, 342-7	17
2024	Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. 2003 , 89, 1155-8	13
2023	A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. 2003 , 89, 1901-5	13
2022	Correlation of early metastatic response by ¹²³ I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. 2003 , 21, 2486-91	122
2021	Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. 2003 , 21, 3826-35	152
2020	Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. 2003 , 21, 4604-10	267
2019	Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. 2003 , 14, 1518-24	54

2018	The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. 2003 , 21, 3683-95	99
2017	Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. 2003 , 14, 197-204	34
2016	Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. 2003 , 21, 1285-92	369
2015	Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. 2003 , 14, 1634-9	32
2014	Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. 2003 , 21, 2651-7	445
2013	An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. 2003 , 14, 1406-11	10
2012	Antitumoral effect of a vaccination procedure with an autologous hemoderivative. 2003 , 2, 155-60	7
2011	Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. 2003 , 22, 1117	3
2010	Response evaluation criteria in solid tumours (RECIST): problems and need for modifications in paediatric oncology?. 2003 , 76, 433-6	29
2009	Imaging in antiangiogenesis trial: a clinical trials radiology perspective. 2003 , 76 Spec No 1, S92-6	10
2008	The role of functional and molecular imaging in cancer drug discovery and development. 2003 , 76 Spec No 2, S128-38	50
2007	STATISTICS USED IN QUALITY CONTROL, QUALITY ASSURANCE, AND QUALITY IMPROVEMENT IN RADIOLOGICAL STUDIES. 2003 , 101-156	1
2006	A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. 2003 , 14, 543-8	13
2005	Präoperative Diagnostik bei gastrointestinalen Stromatumoren. 2003 , 38, 366-373	1
2004	Update on the treatment of neuroendocrine tumors. 2003 , 3, 631-42	18
2003	Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. 2003 , 228, 63-9	92
2002	[Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib]. 2003 , 175, 791-8	7
2001	HIV-related lung cancer in the era of highly active antiretroviral therapy. 2003 , 17, 371-5	111

2000	Radiological measurement of breast cancer metastases to lung and liver: comparison between WHO (bidimensional) and RECIST (unidimensional) guidelines. 2003 , 27, 380-4	33
1999	Magnetic resonance imaging scanner reliability for measuring changes in vestibular schwannoma size. 2003 , 24, 666-70; discussion 670-1	21
1998	Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. 2003 , 15, 323-7	11
1997	On Comparison of Two Classification Methods with Survival Endpoints. 2003 , 23, 43-59	
1996	Targeted drugs in oncology: New names, new mechanisms, new paradigm. 2003 , 60, 1233-1243	6
1995	ABCs of clinical trials. 2003 , 40-44	
1994	Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study. 2003 , 64, 479-80	12
1993	Principles of palliative chemotherapy. 2003 , 12-21	
1992	Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. 2003 , 21, 3770-6	62
1991	Ovarian cancer: what's new, where next?. 2003 , 4, 19-21	1
1990	SOP 03: Preparation and structure of trial protocols. 2003 , 26 Suppl 6, 11-4	
1989	RADIOLOGIA BASADA EN LA EVIDENCIA: ESTRATEGIA CONCEPTUAL FOCALIZADA PARA LA PRACTICA DE LA IMAGENOLOGIA. 2004 , 10, 109	2
1988	Management of androgen-independent prostate cancer. 2004 , 11, 364-73	37
1987	Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer. 2004 , 19, 369-73	14
1986	Diffusion MR imaging in adult neoplasia. 2004 , 312-328	1
1985	Targeted therapy: ready for prime time?. 2004 , 120, 1-15	3
1984	KIT and PDGF as targets. 2004 , 120, 117-27	2
1983	Clinical Development Issues. 2004 , 287-306	1

1982	Quality and consistency in CT colonography and research reporting. 2004 , 230, 319-23	54
1981	Intraoperative radiation therapy in liver tissue in a pig model: monitoring with dual-modality PET/CT. 2004 , 230, 753-60	15
1980	MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. 2004 , 183, 1159-68	42
1979	Response of progressive fibromatosis to therapy with liposomal doxorubicin. 2004 , 27, 552-6	21
1978	Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?. 2004 , 67, 243-9	35
1977	Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies. 2004 , 34, 707-16	2
1976	Nasopharyngeal carcinoma tumor volume measurement. 2004 , 231, 914-21	41
1975	Volumetric assessment of pulmonary nodules with ECG-gated MDCT. 2004 , 183, 1217-23	34
1974	Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy—a pilot study at 4 T. 2004 , 233, 424-31	275
1973	Treatment endpoints for advanced cholangiocarcinoma. 2004 , 1, 4-5	3
1972	Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. 2004 , 230, 101-8	106
1971	Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. 2004 , 19, 658-65	25
1970	Assessment of analysis-of-variance-based methods to quantify the random variations of observers in medical imaging measurements: guidelines to the investigator. 2004 , 31, 1996-2007	4
1969	Principles of Molecular Oncology. 2004 ,	6
1968	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. 2004 , 15, 1042-7	281
1967	Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. 2004 , 14, 73-96	120
1966	Automated matching of temporally sequential CT sections. 2004 , 31, 3417-24	8
1965	Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. 2004 , 31, 1105-15	60

1964	A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. 2004 , 10, 6086-93	83
1963	A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. 2004 , 10, 3386-95	177
1962	A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. 2004 , 10, 4680-7	53
1961	Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. 2004 , 10, 5418-24	34
1960	Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. 2004 , 199, 1503-11	100
1959	Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?. 2004 , 22, 4051-8	72
1958	Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. 2004 , 22, 4456-62	544
1957	PET-CT modification of RECIST guidelines. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 801-2; author reply 802	9-7 8
1956	Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. 2004 , 10, 3927-33	50
1955	Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. 2004 , 15, 257-60	481
1954	Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. 2004 , 10, 5732-40	89
1953	Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. 2004 , 10, 5038-47	62
1952	Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. 2004 , 15, 921-7	13
1951	Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. 2004 , 22, 3451-7	220
1950	Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. 2004 , 10, 3881-4	51
1949	Development and use of biomarkers in oncology drug development. 2004 , 32 Suppl 1, 106-15	42
1948	Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. 2004 , 10, 7311-7	61
1947	Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. 2004 , 15, 671-9	49

1946	The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. 2004 , 10, 2421-8	57
1945	Targeting Treatment of Soft Tissue Sarcomas. 2004 ,	
1944	Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. 2004 , 22, 2522-31	259
1943	Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. 2004 , 22, 115-9	131
1942	Indications for imatinib mesylate therapy and clinical management. 2004 , 9, 271-81	149
1941	Phase II trial of gefitinib in recurrent glioblastoma. 2004 , 22, 133-42	607
1940	Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. 2004 , 22, 3375-80	62
1939	Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. 2004 , 22, 1646-54	232
1938	Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group. 2004 , 1, 9	8
1937	Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1133-41	9.7 333
1936	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. 2004 , 10, 8195-203	458
1935	Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. 2004 , 22, 3950-7	208
1934	Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. 2004 , 22, 3776-83	482
1933	A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. 2004 , 10, 3365-70	84
1932	Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. 2004 , 10, 6006-12	36
1931	Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. 2004 , 10, 7799-811	74
1930	Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. 2004 , 10, 4383-8	71
1929	Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. 2004 , 10, 5650-5	400

1928	Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. 2004 , 10, 6058-65	32
1927	A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. 2004 , 10, 6764-9	33
1926	FDA drug approval summaries: oxaliplatin. 2004 , 9, 8-12	118
1925	A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. 2004 , 15, 928-32	39
1924	A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. 2004 , 34, 681-5	27
1923	RESPONSE: Re: PET-CT Modification of RECIST Guidelines. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 802-802	9.7 8
1922	Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. 2004 , 22, 1110-7	157
1921	Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. 2004 , 22, 537-56	167
1920	First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. 2004 , 15, 1766-72	82
1919	HER-2 gene amplification can be acquired as breast cancer progresses. 2004 , 101, 9393-8	431
1918	Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. 2004 , 66, 347-52	19
1917	Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study. 2004 , 67, 338-43	9
1916	Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. 2004 , 27, 280-4	5
1915	First clinical experience using a pathotropic injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. 2004 , 24, 177	7
1914	Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. 2004 , 22, 4762-71	476
1913	Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. 2004 , 22, 4523-31	110
1912	Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. 2004 , 22, 785-94	1508
1911	Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. 2004 , 22, 4442-5	200

1910	A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. 2004 , 10, 7812-9	94
1909	The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility. 2004 , 3, 23-32	41
1908	Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. 2004 , 10, 3919-26	106
1907	Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. 2004 , 22, 2532-9	276
1906	Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. 2004 , 22, 4944-50	81
1905	Outcome of patients with HIV-related germ cell tumours: a case-control study. 2004 , 90, 1526-30	21
1904	Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. 2004 , 90, 2256-60	131
1903	Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. 2004 , 22, 1430-8	662
1902	On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. 2004 , 10, 4754-60	45
1901	Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. 2004 , 15, 1816-24	60
1900	Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years. 2004 , 17, 645-53	45
1899	Can we now agree to use the same definition to measure response according to CA-125?. 2004 , 22, 4035-6	17
1898	A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. 2004 , 15, 1115-22	17
1897	Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). <i>Journal of the National Cancer Institute</i> , 2004 , 96, 487-8	9.7 221
1896	Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. 2004 , 15, 64-9	101
1895	A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. 2004 , 15, 665-70	11
1894	Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study. 2004 , 34, 647-53	9
1893	Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. 2004 , 22, 3080-90	157

1892	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2004 ,	7
1891	A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. 2004 , 15, 955-9	185
1890	Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. 2004 , 10, 2237-44	35
1889	Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. 2004 , 22, 1706-12	203
1888	Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. 2004 , 22, 238-43	83
1887	Translational research in cancer complementary and alternative medicine: the National Cancer Institute's Best Case Series Program. 2004 , 8, 212-4	7
1886	Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy. 2004 , 94, 552-8	21
1885	Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?. 2004 , 17, 129-35	13
1884	Outcomes in sinonasal mucosal melanoma. 2004 , 74, 838-42	23
1883	Reliability of X-rays and bone scans for the assessment of changes in skeletal metastases from breast cancer. 2004 , 34, 615-20	6
1882	The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. 2004 , 14, 650-8	120
1881	Dendritic cell immunotherapy: mapping the way. 2004 , 10, 475-80	824
1880	Cancer immunotherapy: moving beyond current vaccines. 2004 , 10, 909-15	2369
1879	Cancer vaccines: pessimism in check. 2004 , 10, 1278-9; author reply 1279-80	40
1878	Cancer vaccines: pessimism in check. 2004 , 10, 1279; author reply 1279-80	16
1877	Reply to "Cancer vaccines: pessimism in check". 2004 , 10, 1279-1280	15
1876	Development of TGF-beta signalling inhibitors for cancer therapy. 2004 , 3, 1011-22	452
1875	Urgent need for a validated tumor response evaluation system for use in immunotherapy. 2004 , 33, 255-6; author reply 257-8	8

1874	Reply to the letter by Horii et al. 2004 , 33, 257-258	1
1873	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). 2004 , 90, 82-6	46
1872	Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?. 2004 , 90, 1349-60	85
1871	A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. 2004 , 90, 2261-7	44
1870	Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. 2004 , 90, 2092-6	19
1869	Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. 2004 , 91, 839-43	29
1868	Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. 2004 , 91, 1459-65	16
1867	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. 2004 , 91, 1996-2004	151
1866	Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. 2004 , 91, 2005-11	21
1865	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. 2004 , 93, 417-21	20
1864	Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?. 2004 , 93, 691-8	33
1863	Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. 2004 , 94, 502-8	27
1862	Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?. 2004 , 94, 409-15	14
1861	Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan. 2004 , 94, 393-7	7
1860	Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. 2004 , 94, 774-8	59
1859	Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-Fluorodeoxyglucose positron emission tomography: preliminary results in three patients. 2004 , 95, 597-602	31
1858	Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. 2004 , 4, 32	23
1857	Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. 2004 , 4, 51	27

1856	Bronchioalveolar cell carcinoma: radiologic appearance and dilemmas in the assessment of response. 2004 , 6, 108-12	14
1855	Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. 2004 , 6, 123-8	124
1854	Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. 2004 , 32, 599-606	29
1853	Reproducibility of linear tumor measurements using PACS: comparison of caliper method with edge-tracing method. 2004 , 14, 519-25	20
1852	Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. 2004 , 14, 1371-9	175
1851	Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. 2004 , 11, 465-75	163
1850	Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. 2004 , 22, 315-22	76
1849	Evaluation of irifulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. 2004 , 22, 343-9	21
1848	Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors. 2004 , 66, 179-85	18
1847	Non-resectable slow-growing meningiomas treated by hydroxyurea. 2004 , 67, 221-6	80
1846	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004 , 350, 2129-39	9266
1845	A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. 2004 , 12, 859-63	28
1844	Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. 2004 , 9, 242-6	31
1843	Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer. 2004 , 9, 113-9	7
1842	Alternate-day oral therapy with TS-1 for advanced gastric cancer. 2004 , 9, 143-8	31
1841	Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. 2004 , 9, 364-8	6
1840	A review of the automated detection of change in serial imaging studies of the brain. 2004 , 17, 158-74	23
1839	18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. 2004 , 18, 669-74	53

1838	Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. 2004 , 28, 257-65	66
1837	[Soft tissue sarcoma]. 2004 , 75, 1165-73	8
1836	Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. 2004 , 53, 125-34	106
1835	Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. 2004 , 53, 633-41	93
1834	Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. 2004 , 53, 220-4	16
1833	A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. 2004 , 54, 331-42	70
1832	PET imaging in pediatric Hodgkin's lymphoma. 2004 , 34, 190-8	92
1831	Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. 2004 , 31, 811-9	97
1830	Neoadjuvant therapy for oesophagogastric cancer. 2004 , 91, 540-51	76
1829	Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. 2004 , 26, 322-30	60
1828	Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. 2004 , 100, 2132-8	21
1827	Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. 2004 , 101, 533-40	27
1826	Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. 2004 , 101, 90-5	16
1825	Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. 2004 , 101, 164-71	84
1824	Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. 2004 , 101, 1623-31	711
1823	Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. 2004 , 101, 1664-71	95
1822	Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study. 2004 , 85, 77-81	25
1821	Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. 2004 , 88, 78-85	348

1820	Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. 2004 , 20, 122-8	104
1819	Tongue carcinoma: tumor volume measurement. 2004 , 59, 59-66	23
1818	Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. 2004 , 60, 741-7	131
1817	Volumetric tumor measurement using three-dimensional ultrasound: in vitro phantom study on measurement accuracy under various scanning conditions. 2004 , 30, 27-34	15
1816	Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?. 2004 , 16, 196-203	14
1815	Malignant pleural mesothelioma. 2004 , 28, 93-174	63
1814	Bone imaging in metastatic breast cancer. 2004 , 22, 2942-53	441
1813	Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. 2004 , 15, 1194-203	242
1812	CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. 2004 , 183, 1619-28	373
1811	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. 2004 , 22, 3238-47	922
1810	A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. 2004 , 10, 3717-27	698
1809	Basic treatment considerations using chemotherapy for patients with small cell lung cancer. 2004 , 18, 309-22	23
1808	Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. 2004 , 11, 1115-24	63
1807	Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. 2004 , 46, 255-61	157
1806	[French experience of gefitinib in non-small cell bronchial carcinoma]. 2004 , 21, 934-42	1
1805	Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 2004 , 350, 2335-42	8493
1804	Immunotherapy for advanced renal cell cancer. 2005 , CD001425	217
1803	Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. 2004 , 43, 71-4	42

1802	Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. 2004 , 43, 93-100	13
1801	Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. 2004 , 44, 241-9	18
1800	Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. 2004 , 43, 317-22	45
1799	Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). 2004 , 44, 251-9	18
1798	A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. 2004 , 45, 77-84	13
1797	Staging and response to therapy of malignant pleural mesothelioma. 2004 , 45 Suppl 1, S59-61	10
1796	Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. 2004 , 46, 247-54	50
1795	Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer. 2004 , 46, 369-75	8
1794	Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. 2004 , 46, 361-8	32
1793	Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. 2004 , 64, 2475-92	19
1792	A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. 2004 , 2, 241-3	24
1791	Anticancer Drug Development Guide. 2004 ,	18
1790	Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. 2004 , 22, 777-84	1496
1789	Méthodologie d'évaluation des thérapeutiques ciblées dans les essais cliniques. perspectives d'avenir. 2004 , 60, 72-78	
1788	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. 2004 , 351, 337-45	4112
1787	Practice and progress in kidney cancer: methodology for novel drug development. 2004 , 171, 2115-21	6
1786	Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. 2004 , 40, 352-7	53
1785	Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. 2004 , 40, 681-8	30

1784	The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine. 2004 , 40, 1566-71	31
1783	Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. 2004 , 40, 1872-7	115
1782	Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. 2004 , 40, 2432-8	20
1781	Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. 2004 , 40, 2748-52	13
1780	Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. 2004 , 30, 1069-76	90
1779	Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. 2004 , 63, 342-7	27
1778	Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. 2004 , 63, 934-9	33
1777	Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study. 2004 , 22, 387-92	9
1776	A statistical simulation study finds discordance between WHO criteria and RECIST guideline. 2004 , 57, 358-65	69
1775	Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties. 2004 , 57, 804-8	12
1774	Marqueurs des cancers digestifs : colon, rectum, pancr�as, foie. 2004 , 19, 279-285	
1773	Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. 2004 , 5, 531-40	181
1772	Clinical trial design in oncology: protocol design. 2004 , 5, 759	4
1771	Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?. 2004 , 77, 260-5; discussion 265	87
1770	Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. 2004 , 43, 63-9	107
1769	Advanced imaging including PET/CT for cardiothoracic surgery. 2004 , 16, 272-82	2
1768	Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. 2004 , 71, 139-46	179
1767	In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. 2004 , 72, 333-9	106

1766	Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. 2004 , 364, 1127-34	1354
1765	High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. 2004 , 27, 535-41	40
1764	Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer. 2004 , 78, 1740-6	11
1763	Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. 2004 , 27, 485-8	96
1762	Sepsis: current status, future prospects. 2004 , 10, 250-64	26
1761	Marqueurs des cancers digestifs : cœlonectum, pancrès, foie?. 2004 , 19, 279-285	1
1760	Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer. 2004 , 126, 1656-66	27
1759	A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. 2004 , 14, 439-42	26
1758	Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus. 2004 , 118, 207-12	17
1757	Complete pathologic responses to preoperative chemoradiation in two patients with adenocarcinoma of the pancreas. 2004 , 28, 103-4	5
1756	Recent advances in CT imaging of liver metastases. 2004 , 10, 104-20	23
1755	Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neckAn EORTC New Drug Development Group Study. 2004 , 40, 2748-2752	34
1754	Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). 2004 , 15, 15-22	2
1753	Manipulating dendritic cell biology for the active immunotherapy of cancer. 2004 , 104, 2235-46	278
1752	Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. 2004 , 103, 435-41	111
1751	Protease inhibitors potentiate chemotherapy-induced neutropenia. 2004 , 104, 2943-6	95
1750	Retrospective analysis of concurrent chemoradiation with the combination of bleomycin, ifosfamide and cisplatin (BIP) for uterine cervical cancer. 2004 , 204, 309-15	2
1749	An Introduction to Dynamic Contrast-Enhanced MRI in Oncology. 2005 , 1-22	6

1748	Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. 2005 , 16, 1029-36	7
1747	Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. 2005 , 128, 3467-74	18
1746	A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. 2005 , 15, 447-51	31
1745	Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. 2005 , 33, 1708-16	114
1744	Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro. 2005 , 28, 148-57	8
1743	Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. 2005 , 28, 158-68	30
1742	Octreotide therapy for advanced hepatocellular carcinoma. 2005 , 39, 333-8	29
1741	Quantitative colorectal cancer perfusion measurement using dynamic contrast-enhanced multidetector-row computed tomography: effect of acquisition time and implications for protocols. 2005 , 29, 59-63	60
1740	Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. 2005 , 28, 496-504	153
1739	Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. 2005 , 28, 505-16	115
1738	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. 2005 , 28, 582-92	252
1737	Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. 2005 , 28, 340-4	28
1736	A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. 2005 , 30, 206-10	25
1735	Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. 2005 , 16, 1129-34	29
1734	Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. 2005 , 40, 134-47	38
1733	Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. 2005 , 16, 1023-8	11
1732	The use of three-dimensional ultrasound micro-imaging to monitor prostate tumor development in a transgenic prostate cancer mouse model. 2005 , 207, 181-9	10
1731	Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. 2005 , 15, 205-7	39

1730	Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. 2005 , 15, 297-304	98
1729	Non-surgical therapies of hepatocellular carcinoma. 2005 , 17, 505-13	30
1728	¹³¹ I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. 2005 , 17, 905-10	15
1727	Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. 2005 , 16, 47-51	3
1726	Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. 2005 , 16, 53-7	8
1725	Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake. 2005 , 26, 9-15	22
1724	Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. 2005 , 61, 1423-31	30
1723	Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. 2005 , 62, 988-94	173
1722	Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. 2005 , 63, 1325-30	36
1721	Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. 2005 , 63, 1400-12	104
1720	Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. 2005 , 63, 1427-31	553
1719	Clinical trial design in hepatocellular carcinoma. 2005 , 19, 119-27	2
1718	A phase I study of moderate-dose radiation therapy and weekly gemcitabine in patients with locally advanced non-small cell lung cancer not suitable for radical chemoradiation therapy. 2005 , 17, 332-6	6
1717	Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. 2005 , 12, 995-1004	61
1716	A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. 2005 , 35, 103-9	29
1715	Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. 2005 , 36, 55-8	10
1714	Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. 2005 , 23, 973-81	158
1713	Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. 2005 , 15, 71-8	223

1712	Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. 2005 , 15, 1658-66	174
1711	Detection of liver metastases under 2 cm: comparison of different acquisition protocols in four row multidetector-CT (MDCT). 2005 , 15, 1881-7	39
1710	Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI. 2005 , 15, 2448-56	28
1709	Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case. 2005 , 35, 157-60	2
1708	Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. 2005 , 12, 99-103	16
1707	Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. 2005 , 15, 593-600	44
1706	Trial design for testing new therapies in ovarian cancer. 2005 , 15 Suppl 3, 258-65	4
1705	Treatment goals in ovarian cancer. 2005 , 15 Suppl 1, 3-11	199
1704	A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. 2005 , 95, 963-8	15
1703	A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. 2005 , 96, 787-90	10
1702	Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer. 2005 , 10, 629-35	1
1701	USEFUL ENDOSCOPIC ULTRASONOGRAPHY TO ASSESS THE EFFICACY OF NEOADJUVANT THERAPY FOR ADVANCED ESOPHAGEAL CARCINOMA: BASED ON THE RESPONSE EVALUATION CRITERIA IN SOLID TUMORS. 2005 , 17, 59-63	12
1700	Gefitinib in advanced non-small cell lung cancer. 2005 , 35, 77-82	
1699	Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. 2005 , 96, 721-8	23
1698	Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma. 2005 , 153, 925-31	18
1697	Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. 2005 , 14, 151-4	15
1696	Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. 2005 , 92, 246-51	30
1695	Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. 2005 , 92, 815-9	27

1694	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. 2005 , 92, 1352-7	55
1693	Lack of clinical efficacy of imatinib in metastatic melanoma. 2005 , 92, 1398-405	224
1692	A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. 2005 , 92, 1846-9	47
1691	Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. 2005 , 92, 1976-83	121
1690	Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. 2005 , 92, 1855-61	293
1689	Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. 2005 , 92, 2129-33	53
1688	Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. 2005 , 92, 2122-8	84
1687	Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. 2005 , 93, 46-53	20
1686	Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. 2005 , 93, 29-34	25
1685	Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies. 2005 , 93, 529-37	15
1684	Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. 2005 , 93, 1230-5	27
1683	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. 2005 , 93, 1334-40	70
1682	Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. 2005 , 11, 311-6	16
1681	Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. 2005 , 201, 359-65	83
1680	Radiopaque coil insertion into breast cancers prior to neoadjuvant chemotherapy. 2005 , 14, 108-17	9
1679	Multidetector CT of the solitary pulmonary nodule. 2005 , 40, 109-25	3
1678	Imaging for lung cancer restaging. 2005 , 40, 182-92	6
1677	New agents in the management of advanced mesothelioma. 2005 , 32, 336-50	35

1676	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. 2005 , 32, S59-62	27
1675	International harmonization of trial parameters in malignant lymphoma. 2005 , 75, 53-4	12
1674	The dynamics of plasma transforming growth factor beta 1 (TGF-beta1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer. 2005 , 41, 208-13	9
1673	North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. 2005 , 6, 361-4	18
1672	A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. 2005 , 6, 460-3	5
1671	Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2. 2005 , 6, 245-9	13
1670	Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. 2005 , 7, 40-6	147
1669	Multicenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902. 2005 , 7, 114-20	9
1668	Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules. 2005 , 7, 202-7	9
1667	Targeting multiple signal transduction pathways in lung cancer. 2005 , 7 Suppl 1, S39-44	18
1666	Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. 2005 , 5, 61	23
1665	Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. 2005 , 96, 103-7	34
1664	Re: "Laparoscopically assisted radical vaginal hysterectomy vs. radical abdominal hysterectomy for cervical cancer: a match controlled study". 2005 , 98, 521-2; author reply 522-3	2
1663	Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. 2005 , 98, 54-8	51
1662	Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer. 2005 , 98, 39-44	12
1661	Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. 2005 , 98, 267-73	35
1660	A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. 2005 , 99, 50-7	61
1659	CA-125 criteria for response evaluation in ovarian cancer. 2005 , 98, 520-1	5

1658	Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. 2005 , 103, 111-8	111
1657	A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. 2005 , 103, 553-8	17
1656	Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study. 2005 , 103, 1388-96	8
1655	A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. 2005 , 103, 1431-8	66
1654	A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. 2005 , 103, 1932-8	78
1653	Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. 2005 , 104, 611-7	23
1652	Pro-gastrin-releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation. 2005 , 104, 811-6	14
1651	A phase II trial of arsenic trioxide in patients with metastatic melanoma. 2005 , 104, 1687-92	54
1650	Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. 2005 , 104, 2449-56	83
1649	Prospective non-randomized trial comparing esophagectomy-followed-by-chemoradiotherapy versus chemoradiotherapy-followed-by-esophagectomy for T4 esophageal cancers. 2005 , 90, 209-19	25
1648	Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. 2005 , 21, 775-83	57
1647	The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. 2005 , 32, 153-62	173
1646	90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. 2005 , 32, 778-87	57
1645	Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. 2005 , 54, 208-18	48
1644	A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. 2005 , 54, 713-9	20
1643	Phase I study of TNFalpha AutoVaccine in patients with metastatic cancer. 2005 , 54, 848-57	28
1642	Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. 2005 , 29, 25-30; discussion 30-1	58
1641	A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. 2005 , 55, 295-300	39

1640	Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer. 2005 , 55, 152-8	5
1639	Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. 2005 , 55, 354-360	16
1638	A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. 2005 , 55, 559-64	12
1637	Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. 2005 , 55, 497-501	28
1636	A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. 2005 , 56, 39-45	25
1635	A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer. 2005 , 56, 138-44	5
1634	Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. 2005 , 13, 381-6	27
1633	Updated treatment approach to hepatocellular carcinoma. 2005 , 40, 225-35	420
1632	Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. 2005 , 131, 300-4	58
1631	Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer. 2005 , 131, 783-8	8
1630	Weekly cisplatin administration concurrent with radiation therapy for locoregionally advanced nasopharyngeal carcinoma. 2005 , 10, 201-3	3
1629	Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients. 2005 , 10, 272-5	2
1628	Teleradiologie in der Onkologie. 2005 , 11, 1166-1176	
1627	Maintenance chemotherapy of stage III epithelial ovarian carcinoma-focusing on individualized maintenance chemotherapy. 2005 , 2, 796-799	
1626	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. 2005 , 7, 116-22	4
1625	Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. 2005 , 7, 307-11	88
1624	Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. 2005 , 23, 563-7	8
1623	Phase II study of perifosine in previously untreated patients with metastatic melanoma. 2005 , 23, 569-75	95

1622	A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. 2005 , 23, 311-5	28
1621	BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR). 2005 , 23, 363-8	7
1620	A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors. 2005 , 23, 555-62	9
1619	A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. 2005 , 23, 445-53	6
1618	Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. 2005 , 23, 455-65	4
1617	A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. 2005 , 23, 479-84	19
1616	A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. 2005 , 23, 123-35	17
1615	Phase II trial of fenretinide in advanced renal carcinoma. 2005 , 23, 179-85	48
1614	Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. 2005 , 23, 263-9	26
1613	A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. 2005 , 89, 165-72	138
1612	A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. 2005 , 90, 157-63	76
1611	Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. 2005 , 91, 1-10	178
1610	Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. 2005 , 65, 178-87	74
1609	Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. 2005 , 44, 449-54	8
1608	Significant responses to platinum-based chemotherapy in renal medullary carcinoma. 2005 , 44, 407-11	55
1607	Prognostische Faktoren und Evaluationskriterien. 2005 , 59-66	
1606	Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer. 2005 , 14, 689	
1605	Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. 2005 , 23, 3104-11	118

1604	Potential of PET in oncology and radiotherapy. 2005 , Supplement_28, 6-16	5
1603	Clinical Presentation. 2005 , 63-85	7
1602	Translational Research (Overview of Phase I, II and III Clinical Trials). 2005 ,	
1601	. 2005 ,	53
1600	Quality of life in gastric cancer. 2005 , 11, 3189-96	48
1599	Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study. 2005 , 20, 966-70	13
1598	Use of Dynamic Contrast-Enhanced MRI in Multi-Centre Trials with Particular Reference to Breast Cancer Screening in Women at Genetic Risk. 2005 , 265-279	
1597	A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. 2005 , 16, 1811-6	109
1596	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 2005 , 2, e17	1160
1595	Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. 2005 , 23, 6043-53	880
1594	Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. 2005 , 16, 1081-6	189
1593	New imaging techniques in cancer management. 2005 , 16 Suppl 2, ii63-70	13
1592	Genetically modified dendritic cells for cancer immunotherapy. 2005 , 5, 619-28	53
1591	Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. 2005 , 10, 710-7	20
1590	Gene profile and response to treatment. 2005 , 16 Suppl 2, ii195-202	11
1589	Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer. 2005 , 35, 233-8	9
1588	Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. 2005 , 35, 507-13	18
1587	Capecitabine as third line therapy in patients with advanced colorectal cancer. 2005 , 44, 236-9	20

1586	Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. 2005 , 8, 364-8	10
1585	From traditional biomarkers to transcriptome analysis in drug development. 2005 , 5, 29-38	34
1584	Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. 2005 , 23, 9097-104	102
1583	Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor. 2005 , 1, 93-108	5
1582	MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. 2005 , 184, 1774-81	223
1581	Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. 2005 , 11, 7692-9	31
1580	A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. 2005 , 10, 392-8	41
1579	Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. 2005 , 23, 5305-13	548
1578	Advances in paediatric tumour imaging. 2005 , 90, 608-11	20
1577	Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. 2005 , 11, 1504-11	80
1576	Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. 2005 , 16, 1498-502	11
1575	Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 2005 , 23, 3502-8	543
1574	Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. 2005 , 23, 9113-9	101
1573	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. 2005 , 11, 5539-48	234
1572	Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. 2005 , 11, 3750-7	269
1571	Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. 2005 , 23, 1439-46	168
1570	Randomized phase II evaluation of 6 g/m ² of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m ² of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. 2005 , 23, 105-12	58
1569	PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. 2005 , 16, 1654-61	79

1568	Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials. 2005 , 35, 601-6	11
1567	Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. 2005 , 11, 7434-43	150
1566	Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. 2005 , 11, 3025-31	61
1565	Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. 2005 , 11, 3210-6	109
1564	Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. 2005 , 11, 5487-95	23
1563	Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. 2005 , 23, 5597-604	106
1562	Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. 2005 , 23, 3545-51	85
1561	Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. 2005 , 23, 3069-73	27
1560	Phase I trial of combretastatin a-4 phosphate with carboplatin. 2005 , 11, 1527-33	91
1559	Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. 2005 , 23, 3568-76	233
1558	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. 2005 , 23, 2726-34	201
1557	Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. 2005 , 175, 7746-54	278
1556	Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. 2005 , 11, 5942-9	5
1555	Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. 2005 , 23, 8679-87	54
1554	Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. 2005 , 23, 3726-32	74
1553	Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. 2005 , 11, 6240-6	41
1552	Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. 2005 , 11, 3335-41	7
1551	Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. 2005 , 23, 8992-9000	26

1550	Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). 2005 , 16, 253-8	65
1549	Non-small-cell lung cancer vaccine therapy: a concise review. 2005 , 23, 9022-8	50
1548	Imaging of the patient with non-small cell lung cancer. 2005 , 237, 803-18	42
1547	Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. 2005 , 23, 2534-43	336
1546	Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. 2005 , 23, 1859-66	57
1545	Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. 2005 , 35, 433-8	12
1544	Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. 2005 , 23, 889-98	24
1543	Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. 2005 , 16, 847-62	54
1542	Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. 2005 , 11, 3806-13	61
1541	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. 2005 , 23, 5323-33	286
1540	Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. 2005 , 23, 6881-9	527
1539	Visualization of a primary anti-tumor immune response by positron emission tomography. 2005 , 102, 17412-7	69
1538	Informatics in radiology (infoRAD): new tools for computer assistance in thoracic CT part 2. Therapy monitoring of pulmonary metastases. 2005 , 25, 841-8	31
1537	Pulmonary metastases: effect of CT section thickness on measurement--initial experience. 2005 , 234, 934-9	47
1536	Radiologische Messverfahren zur Beurteilung des Therapieansprechens solider Tumoren. 2005 , 5, 261-272	
1535	Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib. 2005 , 43, 267-73	5
1534	A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. 2005 , 35, 727-32	11
1533	Outcome of dogs with high-grade soft tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996-2004). 2005 , 227, 1442-8	46

1532	99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. 2005 , 111, 363-80	9
1531	Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. 2005 , 235, 892-8	120
1530	Quantitative assessment of colorectal cancer perfusion using MDCT: inter- and intraobserver agreement. 2005 , 185, 225-31	62
1529	Risks and benefits of phase 1 oncology trials, 1991 through 2002. 2005 , 352, 895-904	339
1528	Prevention of high-dose melphalan-induced mucositis by cryotherapy. 2005 , 46, 633-4	15
1527	Outcomes of postmastectomy radiotherapy. 2005 , 172, 18; author reply 19	
1526	Patient-physician-regulator triad. 2005 , 172, 15; author reply 18	
1525	Patient-physician-regulator triad. 2005 , 172, 18-18	78
1524	A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. 2005 , 69, 117-21	18
1523	Radiologic assessment of rectosigmoid cancer before and after neoadjuvant radiation therapy: comparison between quantitation techniques. 2005 , 184, 526-30	12
1522	Historical Review of Research and Treatment of Gastric Cancer in Japan: Clinical Aspect. 2005 , 29-47	4
1521	Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 2005 , 23, 792-9	1151
1520	PET for response assessment in oncology: radiotherapy and chemotherapy. 2005 , Supplement_28, 42-49	21
1519	A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity. 2005 , 20, 479-86	3
1518	Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. 2005 , 65, 8079-84	114
1517	Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. 2005 , 23, 8362-70	221
1516	Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. 2005 , 23, 2332-8	258
1515	Chemosensitivity: Volume II. 2005 ,	3

1514	Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. 2005 , 16, 1054-60	49
1513	Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. 2005 , 16, 1688-94	237
1512	Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. 2005 , 92, 634-8	8
1511	Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. 2005 , 93, 979-85	30
1510	Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. 2005 , 93, 999-1004	33
1509	Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. 2005 , 93, 190-4	79
1508	Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. 2005 , 23, 7889-96	253
1507	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. 2005 , 23, 6657-63	390
1506	Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. 2005 , 11, 4289-94	107
1505	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. 2005 , 23, 2502-12	302
1504	Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. 2005 , 23, 5464-73	249
1503	Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. 2005 , 23, 8033-40	398
1502	Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2005 , 11, 8418-24	201
1501	Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. 2005 , 23, 3912-22	351
1500	Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. 2005 , 23, 6172-80	92
1499	Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. 2005 , 23, 5795-804	239
1498	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. 2005 , 23, 2544-55	497
1497	Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. 2005 , 11, 7911-9	20

1496	The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 2005 , 68, 212-6	3
1495	Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. 2005 , 23, 7445-53	232
1494	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. 2005 , 23, 6838-45	513
1493	Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. 2005 , 23, 7794-803	1618
1492	Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. 2005 , 20, 379-90	25
1491	Tumor Immunology and Cancer Vaccines. 2005 ,	2
1490	Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. 2005 , 23, 455-60	170
1489	Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. 2005 , 23, 5474-83	421
1488	Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. 2005 , 23, 5779-87	153
1487	Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. 2005 , 23, 5613-9	88
1486	Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. 2005 , 23, 5929-37	64
1485	A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. 2005 , 65, 6337-45	76
1484	FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. 2005 , 11, 4770-4	26
1483	Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. 2005 , 11, 8674-9	40
1482	Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. 2005 , 51, 132-41	17
1481	Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. 2005 , 10, 718-27	32
1480	Prostate cancer clinical trial end points: "RECIST"ing a step backwards. 2005 , 11, 5223-32	116
1479	Clinical trials in ovarian carcinoma: study methodology. 2005 , 16 Suppl 8, viii20-viii29	18

1478	Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. 2005 , 23, 9089-96	141
1477	Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. 2005 , 23, 7785-93	239
1476	Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. 2005 , 11, 8201-7	48
1475	Chemotherapy options and new advances in malignant pleural mesothelioma. 2005 , 16, 345-51	45
1474	Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. 2005 , 11, 5472-80	313
1473	Epithelial membrane protein-1 is a biomarker of gefitinib resistance. 2005 , 102, 11858-63	74
1472	Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. 2005 , 16, 300-6	22
1471	Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. 2005 , 35, 316-23	90
1470	Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. 2005 , 23, 1867-74	148
1469	Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. 2005 , 11, 2300-4	221
1468	Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. 2005 , 23, 8786-93	172
1467	Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. 2005 , 11, 1854-62	65
1466	Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. 2005 , 11, 1870-6	25
1465	Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. 2005 , 68, 493-9	40
1464	Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. 2005 , 28, 73-8	4
1463	Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. 2005 , 68, 190-5	35
1462	Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. 2005 , 69, 261-8	16
1461	Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. 2005 , 28, 195-8	7

1460	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. 2005 , 28, 623-7	3
1459	Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. 2005 , 69, 363-71	46
1458	Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. 2005 , 27, 1039	3
1457	Image-guided tumor ablation: standardization of terminology and reporting criteria. 2005 , 235, 728-39	565
1456	Effect of CT image compression on computer-assisted lung nodule volume measurement. 2005 , 237, 83-8	24
1455	A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. 2005 , 11, 4144-50	4
1454	Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. 2005 , 11, 6650-6	132
1453	Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. 2005 , 23, 585-90	225
1452	A phase II study of perifosine in androgen independent prostate cancer. 2005 , 4, 1133-7	88
1451	Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b. 2005 , 17, 674-8	1
1450	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). 2005 , 366, 1527-37	1802
1449	A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. 2005 , 173, 790-6	62
1448	Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. 2005 , 6, 383-91	170
1447	A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. 2005 , 76, 54-8	8
1446	A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. 2005 , 77, 143-7	19
1445	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. 2005 , 23, 5007-18	333
1444	Erlotinib in lung cancer - molecular and clinical predictors of outcome. 2005 , 353, 133-44	1594
1443	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 643-55	9.7 1367

1442	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. 2005 , 23, 2513-20	839
1441	The radiologic measurement of mesothelioma. 2005 , 19, 1053-66, vi	2
1440	Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. 2005 , 23, 965-72	755
1439	90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. 2005 , 16, 1641-51	152
1438	Imaging and response in soft tissue sarcomas. 2005 , 19, 471-87, vi	35
1437	Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. 2005 , 16, 1627-39	346
1436	Real-time MRI monitoring of transcatheter hepatic artery contrast agent delivery in rabbits. 2005 , 12, 1342-50	7
1435	Tumor response assessment is more robust with sequential CT scanning than external caliper measurements. 2005 , 12, 776-81	18
1434	Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. 2005 , 12, 1301-9	29
1433	Monitoring response to treatment in patients utilizing PET. 2005 , 43, 189-204	129
1432	The Diversity of Gastric Carcinoma. 2005 ,	2
1431	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology. 2005 ,	54
1430	Oxaliplatin (Eloxatin) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma. 2005 , 15, 614-7	2
1429	Vinflunine: a novel antitubulin agent in solid malignancies. 2005 , 14, 1259-67	36
1428	Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. 2005 , 23, 296-302	16
1427	Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 2005 , 23, 3706-12	551
1426	Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 2005 , 23, 3697-705	762
1425	Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. 2005 , 23, 7135-42	218

1424	Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. 2005 , 11, 5878-85	295
1423	Predictors of the response to gefitinib in refractory non-small cell lung cancer. 2005 , 11, 2244-51	161
1422	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. 2005 , 23, 5892-9	1267
1421	Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. 2005 , 23, 576-84	350
1420	Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. 2005 , 68, 382-90	21
1419	A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. 2005 , 58, 150-3	11
1418	OncoTREAT [®] software assistant for oncological therapy monitoring. 2005 , 1281, 429-434	3
1417	Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. 2005 , 11, 297-306	5
1416	Capecitabine: a review. 2005 , 27, 23-44	456
1415	Pemetrexed: a multitargeted antifolate. 2005 , 27, 1343-82	91
1414	Medical imaging in pharmaceutical clinical trials: what radiologists should know. 2005 , 60, 1051-7	37
1413	Use of imaging in the management of malignant pleural mesothelioma. 2005 , 60, 1237-47	53
1412	Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naïve metastatic breast cancer patients. 2005 , 41, 249-55	8
1411	Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. 2005 , 41, 386-92	39
1410	Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. 2005 , 41, 555-63	49
1409	New science-based endpoints to accelerate oncology drug development. 2005 , 41, 491-501	75
1408	Assessment of the value of confirming responses in clinical trials in oncology. 2005 , 41, 1528-32	7
1407	Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. 2005 , 41, 1431-8	22

1406	Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. 2005 , 41, 1533-41	146
1405	RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. 2005 , 41, 1426-30	55
1404	Confirmation of response in cancer clinical trials: a meaningless exercise?. 2005 , 41, 1501-2	1
1403	Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. 2005 , 41, 1751-7	298
1402	Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. 2005 , 31, 67-73	50
1401	Hand-assisted laparoscopic and thoracoscopic surgery (HALTS) in radical esophagectomy with three-field lymphadenectomy for thoracic esophageal cancer. 2005 , 31, 1166-74	20
1400	Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. 2005 , 65, 543-8	19
1399	A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. 2005 , 23, 143-9	45
1398	Alcohol abuse predicts progression of disease and death in patients with lung cancer. 2005 , 80, 1033-9	27
1397	Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. 2005 , 190, 371-5	30
1396	[Evaluation of response to neoadjuvant chemotherapy using breast scintigraphy in breast cancer]. 2005 , 125, 601-5	1
1395	Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. 2005 , 3, 17	46
1394	The emergence of modern cancer immunotherapy. 2005 , 12, 344-6	12
1393	Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. 2005 , 44, 147-73	85
1392	Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. 2005 , 5, 50-6	28
1391	Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. 2005 , 5, 181-7	15
1390	FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. 2005 , 5, 263-7	24
1389	Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. 2005 , 4, 91-9	11

1388	Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. 2005 , 4, 113-7	2
1387	SU11248 and AG013736: current data and future trials in renal cell carcinoma. 2005 , 4, 175-80	16
1386	References. 2005 , 246-254	
1385	Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation. 2005 , 3, 373-82, 422	14
1384	Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. 2005 , 47, 129-38	118
1383	Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC). 2005 , 47, 395-404	11
1382	Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. 2005 , 48, 267-73	42
1381	Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. 2005 , 48, 429-34	47
1380	Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). 2005 , 48, 399-407	19
1379	Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. 2005 , 49, 209-15	9
1378	Computerized analysis of mesothelioma on CT scans. 2005 , 49 Suppl 1, S41-4	2
1377	CT, RECIST, and malignant pleural mesothelioma. 2005 , 49 Suppl 1, S37-40	33
1376	Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. 2005 , 50, 83-6	111
1375	Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. 2005 , 50, 107-14	7
1374	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. 2005 , 50, 25-33	70
1373	Phase II trials in mesothelioma: an increasing challenge. 2005 , 50, 87-90	2
1372	Imaging of non-small cell lung cancer. 2005 , 43, 467-80, vii	1
1371	The role of PET in monitoring therapy. 2005 , 5, 51-7	39

1370	Image-guided tumor ablation: standardization of terminology and reporting criteria. 2005 , 16, 765-78	246
1369	The potential power of reference image databases and oncologic imaging. 2005 , 2, 565-7	1
1368	Salvage Therapy with Capecitabine Plus Weekly Paclitaxel in Heavily Pretreated Advanced Breast Cancer. 2005 , 4, 307-313	4
1367	Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. 2005 , 4, 329-50	48
1366	Genomics in breast cancer-therapeutic implications. 2005 , 2, 26-33	41
1365	Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. 2005 , 23, 1028-43	326
1364	Assessing the minimally clinically significant difference: scientific considerations, challenges and solutions. 2005 , 2, 57-62	113
1363	Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. 2005 , 50, 393-9	15
1362	Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. 2005 , 69, 326-32	24
1361	Erlotinib in previously treated non-small-cell lung cancer. 2005 , 353, 123-32	4590
1360	Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. 2005 , 7, R436-43	115
1359	Deciphering cellular states of innate tumor drug responses. 2006 , 7, R19	97
1358	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. 2006 , 95, 998-1004	244
1357	A Phase II Study with Antioxidants, both in the Diet and Supplemented, Pharmaco-Nutritional Support, Progestagen and Anti-COX-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia-Cachexia and Oxidative Stress. 2006 , 685-698	
1356	Lung cancer and radiofrequency ablation. 2006 , 17, 927-51; quiz 951	78
1355	Morphological segmentation and partial volume analysis for volumetry of solid pulmonary lesions in thoracic CT scans. 2006 , 25, 417-34	197
1354	[Pleural mesothelioma: imaging contribution]. 2006 , 62, 117-23	
1353	Histopathologic and Metabolic Criteria for Assessment of Treatment Response in Breast Cancer. 2006 , 1, 83-94	

1352	Pharmacodynamic biomarkers for molecular cancer therapeutics. 2007 , 96, 213-68	124
1351	The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. 2006 , 17, 505-12	175
1350	Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. 2006 , 24, 310-7	39
1349	Image guided respiratory gated hypofractionated Stereotactic Body Radiation Therapy (H-SBRT) for liver and lung tumors: Initial experience. 2006 , 45, 881-9	101
1348	Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. 2006 , 6, 951-62	6
1347	Dendritic cell-based immunotherapy. 2006 , 25, 377-413	84
1346	Albumin-bound paclitaxel: a next-generation taxane. 2006 , 7, 1041-53	463
1345	XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. 2006 , 94, 969-75	103
1344	Assessment of tumor response on MR imaging after locoregional therapy. 2006 , 9, 125-32	76
1343	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. 2006 , 24, 64-9	147
1342	Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. 2006 , 7, 521-3	67
1341	Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. 2006 , 7, 741-6	135
1340	Marcos históricos no estudo do cancro do pulmão. 2006 , 12, 401-446	3
1339	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. 2006 , 368, 1329-38	2004
1338	Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. 2006 , 55, 1432-42	73
1337	Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. 2006 , 17, 1425-39	173
1336	Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. 2006 , 29, 308-13	39
1335	Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer. 2006 , 69, 304-9	5

1334	A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. 2006 , 79, 34-8	46
1333	Molecular responses of rectal cancer to preoperative chemoradiation. 2006 , 80, 172-7	30
1332	Use of an arterial tourniquet to achieve complete radiofrequency ablation of a renal metastasis. 2006 , 17, 1051-5	3
1331	Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. 2006 , 3, 668-81	258
1330	Reporting standards for percutaneous thermal ablation of renal cell carcinoma. 2006 , 17, 1563-70	33
1329	Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. 2006 , 17, 1195-200	98
1328	MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. 2006 , 14, 383-9, vii	37
1327	Variability in size measurement of renal masses smaller than 4 cm on computerized tomography. 2006 , 176, 2386-90; discussion 2390	29
1326	Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. 2006 , 4, 211-9	22
1325	Albumin-bound Paclitaxel: in metastatic breast cancer. 2006 , 66, 941-8	24
1324	Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. 2006 , 7, 237-43	32
1323	A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. 2006 , 7, 401-5	19
1322	Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. 2006 , 5, 429-35	3
1321	A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors. 2006 , 6, 72-5	3
1320	Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. 2006 , 6, 125-32	147
1319	Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials. 2006 , 6 Suppl 1, S24-9	13
1318	Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer. 2006 , 5, 155-61	11
1317	Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. 2006 , 5, 212-8	4

1316	Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. 2006 , 6, 342-7	17
1315	[Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors]. 2006 , 25, 80-8	6
1314	[Medical errors in oncology and patient safety]. 2006 , 126, 779-81	0
1313	Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. 2006 , 4, 16	11
1312	Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. 2006 , 4, 35	25
1311	Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. 2006 , 4, 36	35
1310	Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. 2006 , 13, 776-82	198
1309	Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. 2006 , 244, 176-84	196
1308	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. 2006 , 51, 71-7	49
1307	Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion. 2006 , 51, 217-23	5
1306	Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. 2006 , 51, 237-43	15
1305	Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. 2006 , 52, 173-80	29
1304	Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. 2006 , 52, 141-8	50
1303	Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. 2006 , 53, 51-8	32
1302	A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. 2006 , 52, 333-8	8
1301	A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. 2006 , 52, 305-11	8
1300	Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. 2006 , 53, 77-83	19
1299	A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. 2006 , 53, 197-203	25

1298	A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. 2006 , 53, 189-95	14
1297	Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer. 2006 , 53, 177-81	1
1296	A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. 2006 , 54, 69-77	33
1295	Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). 2006 , 53, 347-53	18
1294	Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. 2006 , 53, 311-22	64
1293	PET/CT imaging in response evaluation of patients with small cell lung cancer. 2006 , 54, 41-9	46
1292	Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimetabolic agents combined with platinum chemotherapy. 2006 , 54, 217-25	35
1291	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. 2006 , 54, 193-9	32
1290	Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. 2006 , 54, 331-8	9
1289	A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. 2006 , 54, 365-70	16
1288	Design and Analysis of Oncology Clinical Trials. 2006 , 112-126	2
1287	Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. 2006 , 24, 1729-44	50
1286	Comparison of CT during arterial portography and MR during arterial portography in the detection of liver metastases. 2006 , 186, 1502-11	11
1285	Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. 2006 , 24, 2549-56	305
1284	Clinical activity of pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. 2006 , 24, 4324-32	209
1283	Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. 2006 , 17, 1263-8	427
1282	Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. 2006 , 24, 5716-24	186
1281	Cancer regression in patients after transfer of genetically engineered lymphocytes. 2006 , 314, 126-9	2001

1280	Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. 2006 , 95, 848-52	103
1279	Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. 2006 , 24, 668-74	361
1278	Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. 2006 , 28, 1779-802	392
1277	Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. 2006 , 12, 346-54	9
1276	Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. 2006 , 12, 778-85	33
1275	[Treatment response evaluation by functional imaging]. 2006 , 10, 484-7	2
1274	Hormone refractory prostate cancer: Management and advances. 2006 , 32, 90-100	24
1273	A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. 2006 , 42, 200-4	20
1272	A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer. 2006 , 42, 193-9	8
1271	Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. 2006 , 42, 171-8	35
1270	Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. 2006 , 42, 548-56	150
1269	Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. 2006 , 42, 864-70	19
1268	Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. 2006 , 42, 1768-74	75
1267	RECIST revisited: a review of validation studies on tumour assessment. 2006 , 42, 1031-9	352
1266	Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984). 2006 , 42, 1399-406	17
1265	Update in methodology and conduct of cancer clinical trials. 2006 , 42, 1322-30	27
1264	To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. 2006 , 42, 2472-9	137
1263	Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. 2006 , 42, 2318-25	51

1262	Methodological issues in the economic analysis of cancer treatments. 2006 , 42, 2867-75	67
1261	A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. 2006 , 42, 2751-6	31
1260	Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). 2006 , 42, 3161-8	38
1259	Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up. 2006 , 59, 42-8	5
1258	Dynamic enhanced MRI predicts chemosensitivity in breast cancer patients. 2006 , 60, 270-4	32
1257	Clinical activity of celecoxib in metastatic malignant melanoma. 2006 , 24, 740-6	15
1256	Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. 2006 , 55, 429-37	104
1255	Imaging response assessment in oncology. 2006 , 6, S126-30	45
1254	Efficacy of Chemotherapy in Patients With Asymptomatic Brain Metastases From Non-small Cell Lung Cancer. 2006 , 46, 111-116	
1253	FDG-PET in colorectal cancer. 2006 , 6, S71-81	36
1252	Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. 2006 , 16, 57	3
1251	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. 2006 , 92, 384-388	12
1250	Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases. 2006 , 29, 225-231	76
1249	Gene Expression Profiling to Predict Chemotherapy Response in Primary Breast Cancer. 2006 , 1, 362-367	2
1248	Response to chemotherapy in patients with lung metastases: how many nodules should be measured?. 2006 , 6, 107-12	5
1247	DEVISING PROOF-OF-CONCEPT STRATEGIES IN ONCOLOGY CLINICAL TRIALS. 2006 , 337-364	
1246	Imaging of hepatic metastases. 2006 , 13, 6-12	33
1245	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. 2006 , 1, 847-855	101

1244 Clinical Trial Design and Implementation. **2006**, 105-112

1243 Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. **2006**, 20, 157-63 98

1242 A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma. **2006**, 2006, 64374 23

1241 CT in Carcinoma of the Ovary. 132-155 0

1240 PET and PET/CT in Ovarian Cancer. 156-172

1239 Association between Immunohistochemical Expression of Topoisomerase II β , Her2 and Hormone Receptors and Response to Primary Chemotherapy in Breast Cancer. **2006**, 92, 222-229 6

1238 Systemic treatment of malignant thymoma: a decade experience at a single institution. **2006**, 29, 336-44 36

1237 The paradox of response and survival in cancer therapeutics. **2006**, 107, 431-4 126

1236 Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. **2006**, 107, 3795-803 41

1235 Pre-Treatment Prediction of Chemoresistance in Second-Line Chemotherapy of Ovarian Carcinoma: Value of Serological Tumor Marker Determination (Tetranectin, YKL-40, CASA, CA 125). **2006**, 21, 141-148 15

1234 Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. **2006**, 4, 955-66 14

1233 A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501). **2006**, 1, 673-678 3

1232 DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. **2006**, 1, 984-990 27

1231 Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study. **2006**, 1, 328-334 13

1230 Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer. **2006**, 1, 810-815 28

1229 A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer. **2006**, 1, 19-24 5

1228 Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients with Advanced Non-small Cell Lung Cancer. **2006**, 1, 832-836 4

1227 Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. **2006**, 1, 506-512 42

1226	Short-Term Restaging of Patients with Non-small Cell Lung Cancer Receiving Chemotherapy. 2006 , 1, 425-429	4
1225	Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer. 2006 , 1, 679-683	19
1224	Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?. 2006 , 1, 684-691	4
1223	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 1010-1019	1
1222	Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors. 2006 , 1, 802-809	55
1221	Docetaxel Consolidation Therapy Following Cisplatin, Vinorelbine, and Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non-small Cell Lung Cancer. 2006 , 1, 810-815	33
1220	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. 2006 , 1, 126-134	7
1219	EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. 2006 , 1, 260-7	60
1218	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. 2006 , 1, 787-795	6
1217	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	
1216	Short-Term Restaging of Patients with Non-small Cell Lung Cancer Receiving Chemotherapy. 2006 , 1, 425-429	4
1215	Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer. 2006 , 1, 679-683	40
1214	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. 2006 , 1, 847-855	140
1213	Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group. 2006 , 1, 447-453	5
1212	Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. 2006 , 12, 212-21	46
1211	Chimiothérapie des cancers digestifs : généralités et principaux cytotoxiques utilisés. 2006 , 1, 1-4	
1210	A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non-small-Cell Lung Cancer. 2006 , 1, 19-24	10
1209	New approaches in hormone refractory prostate cancer. 2006 , 29, 196-201	11

1208	Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. 2006 , 25, 131-9	18
1207	Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. 2006 , 17, 207-15	49
1206	[Historic landmarks in the study of lung cancer]. 2006 , 12, 401-46	1
1205	Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. 2006 , 1, 506-512	46
1204	Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027). 2006 , 1, 537-544	4
1203	A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501). 2006 , 1, 673-678	5
1202	Newer Issues in Mesothelioma Chemotherapy. 2006 , 1, 177-179	2
1201	Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. 2006 , 1, 218-25	7
1200	Phase Ia/Ib Chemo-Radiation Trial of Gemcitabine and Dose-Escalated Thoracic Radiation in Patients with Stage III A/B Non-small Cell Lung Cancer. 2006 , 1, 434-440	
1199	Volumetric analysis of liver metastases in computed tomography with the fuzzy C-means algorithm. 2006 , 30, 212-20	16
1198	Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial. 2006 , 1, 289-295	43
1197	Traitements non chirurgicaux des tumeurs des os: chimiothérapie et radiothérapie. 2006 , 1, 1-7	
1196	Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. 2006 , 1, 211-7	6
1195	Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study. 2006 , 1, 328-334	20
1194	Phase II Study of Carboplatin Combined with Biweekly Docetaxel for Advanced Non-small Cell Lung Cancer. 2006 , 1, 979-983	1
1193	The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline. 2006 , 1, 591-601	29
1192	Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?. 2006 , 27, 413-6	3
1191	Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 832-836	10

1190	Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. 2006 , 17, 337-43	20
1189	DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. 2006 , 1, 984-990	30
1188	Reply. 2006 , 187, W553-W553	
1187	Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. 2006 , 29, 545-57	194
1186	A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. 2006 , 17, 1067-73	12
1185	Phase II study of 3-week scheduling of irinotecan in combination with cisplatin in patients with advanced nonsmall-cell lung cancer. 2006 , 29, 503-7	2
1184	Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer. 2006 , 29, 87-94	28
1183	Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. 2006 , 29, 95-101	23
1182	A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer. 2006 , 29, 3-7	1
1181	Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. 2006 , 17, 81-7	3
1180	Inpatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. 2006 , 29, 455-63	222
1179	Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. 2006 , 29, 919	3
1178	Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. 2006 , 59, 988-99; discussion 999-1000	56
1177	Sorafenib. 2006 , 18, 615-21	55
1176	Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. 2006 , 17, 401-9	117
1175	Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. 2006 , 17, 855-7	93
1174	A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. 2006 , 16, 245-8	43
1173	The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. 2006 , 29, 40-4	12

1172	A phase II study of higher dose docetaxel in androgen-independent prostate cancer. 2006 , 29, 389-94	4
1171	Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. 2006 , 29, 576-82	11
1170	Monitoring of lung motion in patients with malignant pleural mesothelioma using two-dimensional and three-dimensional dynamic magnetic resonance imaging: comparison with spirometry. 2006 , 41, 443-8	24
1169	Operator-dependent reproducibility of size measurements of small phantoms and lung nodules examined with low-dose thin-section computed tomography. 2006 , 41, 831-9	9
1168	Interstitial hyperthermia with intra-arterial injection of adriamycin for malignant glioma. 2006 , 46, 19-23; discussion 23	8
1167	Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. 2006 , 46, 127-34	34
1166	A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. 2006 , 46, 345-50	7
1165	Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. 2006 , 47, 865-74	71
1164	Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. 2006 , 84, 295-302	16
1163	Development of growth inhibitory agents in urological and other malignancies. 2006 , 98, 497-502	
1162	Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. 2006 , 98, 756-62	98
1161	Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. 2006 , 11, 287-91	6
1160	Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. 2006 , 19, 473-6	19
1159	The importance of PET in the diagnosis and response evaluation of esophageal cancer. 2006 , 19, 433-42	67
1158	Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. 2006 , 36, 367-77	6
1157	Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. 2006 , 16, 52-6	53
1156	Primary peritoneal carcinoma: experience with cytoreductive surgery and combination chemotherapy. 2006 , 16, 23-8	10
1155	Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients. 2006 , 16 Suppl 1, 60-7	10

1154	A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. 2006 , 16 Suppl 1, 79-85	13
1153	Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged?. 2006 , 2, 175-179	2
1152	An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. 2006 , 155, 182-5	35
1151	Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. 2006 , 64, 456-62	41
1150	Drug development in oncology: classical cytotoxics and molecularly targeted agents. 2006 , 62, 15-26	128
1149	Effect of the introduction of minimum lesion size on interobserver reproducibility using RECIST guidelines in non-small cell lung cancer patients. 2006 , 97, 214-8	14
1148	High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. 2006 , 97, 642-8	120
1147	Measuring response in a post-RECIST world: from black and white to shades of grey. 2006 , 6, 409-14	152
1146	'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'. 2006 , 94, 69-73	21
1145	Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. 2006 , 94, 427-35	159
1144	FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). 2006 , 94, 798-805	281
1143	Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. 2006 , 94, 792-7	94
1142	A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. 2006 , 94, 959-63	54
1141	A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. 2006 , 94, 964-8	39
1140	Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. 2006 , 94, 1136-43	114
1139	A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. 2006 , 94, 1287-92	35
1138	Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. 2006 , 94, 1383-8	48
1137	Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. 2006 , 94, 1389-94	95

1136	Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. 2006 , 94, 1604-9	70
1135	Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. 2006 , 94, 1621-6	131
1134	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. 2006 , 94, 1797-802	2
1133	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. 2006 , 95, 450-6	9
1132	Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease). 2006 , 95, 470-4	2
1131	Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. 2006 , 95, 853-61	43
1130	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. 2006 , 95, 1390-5	110
1129	Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. 2006 , 95, 1642-7	43
1128	Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect. 2006 , 38, 729-32	7
1127	Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. 2006 , 13, 905-18	156
1126	Role of computed tomography imaging in predicting response of nasopharyngeal carcinoma to definitive radiation therapy. 2006 , 116, 2162-5	9
1125	CT and PET imaging in non-small cell lung cancer. 2006 , 58, 15-30	9
1124	Kinase inhibitors in the treatment of renal cell carcinoma. 2006 , 60, 216-26	26
1123	Analyzing the "correct" endpoint. 2006 , 30, 283-97	
1122	Dealing with multiple endpoints. 2006 , 30, 298-306	1
1121	Functional imaging in clinical oncology: magnetic resonance imaging- and computerised tomography-based techniques. 2006 , 18, 555-70	24
1120	Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. 2006 , 18, 684-92	35
1119	Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors. 2006 , 64, 1179-82	16

1118	Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival. 2006 , 64, 1023-30	30
1117	Feasibility of a novel deformable image registration technique to facilitate classification, targeting, and monitoring of tumor and normal tissue. 2006 , 64, 1245-54	119
1116	High-dose proton beam therapy for Stage I non-small-cell lung cancer. 2006 , 65, 107-11	117
1115	Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. 2006 , 66, 126-34	174
1114	Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. 2006 , 66, 748-53	88
1113	Radioembolization using ⁹⁰ Y-resin microspheres for patients with advanced hepatocellular carcinoma. 2006 , 66, 792-800	181
1112	A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy. 2006 , 66, 992-1003	39
1111	Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. 2006 , 66, 1391-8	27
1110	Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. 2006 , 24, 843-7	322
1109	Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases. 2006 , 10, 249-58	25
1108	Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424. 2006 , 13, 685-98	28
1107	Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. 2006 , 13, 166-71	26
1106	Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles. 2006 , 13, 192-6	6
1105	Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. 2006 , 16, 781-90	127
1104	Monitoring therapeutic efficacy in breast carcinomas. 2006 , 16, 2549-58	44
1103	Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case. 2006 , 36, 727-32	7
1102	Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case. 2006 , 36, 1133-8	6
1101	Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas. 2006 , 1073, 383-91	18

1100	Imaging vascular physiology to monitor cancer treatment. 2006 , 58, 95-113	48
1099	Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. 2007 , 14, 14-24	184
1098	Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. 2006 , 13, 1443-9	73
1097	Advanced colon cancer: antiproliferative immunotherapy using an autologous hemoderivative. 2006 , 23, 91-104	5
1096	Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. 2006 , 24, 203-12	14
1095	Phase I trial of oral talactoferrin alfa in refractory solid tumors. 2006 , 24, 233-40	73
1094	Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. 2006 , 24, 335-41	14
1093	Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. 2006 , 24, 79-83	2
1092	Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. 2006 , 24, 85-8	38
1091	A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). 2006 , 24, 343-6	13
1090	A phase I and pharmacokinetic study of iriflufen and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. 2006 , 24, 311-9	11
1089	A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. 2006 , 24, 141-9	13
1088	Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. 2006 , 24, 159-67	106
1087	A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. 2006 , 24, 435-9	73
1086	A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. 2006 , 24, 441-6	32
1085	Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. 2006 , 24, 521-7	57
1084	A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. 2006 , 24, 515-20	62
1083	Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. 2007 , 25, 77-84	92

1082	Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. 2007 , 25, 63-7	39
1081	Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. 2007 , 25, 161-4	16
1080	A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. 2007 , 25, 181-5	25
1079	A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. 2007 , 25, 123-9	26
1078	A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. 2006 , 24, 543-6	121
1077	Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. 2006 , 8, 141-50	106
1076	Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. 2006 , 8, 300-8	24
1075	Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. 2006 , 98, 241-8	28
1074	Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative. 2006 , 100, 149-60	8
1073	Systemic high-dose intravenous methotrexate for central nervous system metastases. 2006 , 78, 255-60	94
1072	Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer. 2006 , 41, 339-46	4
1071	Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. 2006 , 41, 1099-106	39
1070	Preoperative chemoradiotherapy with concomitant small field boost irradiation for locally advanced rectal cancer: a multi-institutional phase II study (KROG 04-01). 2006 , 49, 1684-91	13
1069	Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. 2006 , 184, 279-85	15
1068	Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. 2006 , 132, 635-42	11
1067	A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. 2006 , 132, 611-6	19
1066	Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer. 2006 , 9, 36-43	3
1065	Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. 2006 , 9, 140-3	3

1064	Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. 2006 , 11, 314-9	1
1063	Unresectable gastric cancer with multiple liver metastases effectively treated with combined paclitaxel and doxifluridine chemotherapy. 2006 , 11, 471-4	3
1062	Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. 2006 , 11, 454-60	23
1061	Biologie: d'croissance du CA-125. A-t-on des indications de pilotage sur les traitements?. 2006 , 8, 132-138	2
1060	Ovarialkarzinom. 2006 , 39, 420-427	
1059	Reliability of CT-based tumor volumetry after intraarterial chemotherapy in patients with small carcinoma of the oral cavity and the oropharynx. 2006 , 48, 415-21	4
1058	Radiological staging in children with hepatoblastoma. 2006 , 36, 176-82	49
1057	Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. 2006 , 33, 412-9	66
1056	(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. 2006 , 33, 344-52	23
1055	Imaging biomarkers as surrogate endpoints for drug development. 2006 , 33 Suppl 1, 6-10	35
1054	Current standards for response evaluation by imaging techniques. 2006 , 33 Suppl 1, 11-5	15
1053	Monitoring chemotherapy and radiotherapy of solid tumors. 2006 , 33 Suppl 1, 27-37	100
1052	Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?. 2006 , 33 Suppl 1, 38-43	28
1051	Putting 'clear' into nuclear medicine: a decade of PET/CT development. 2006 , 33, 857-61	32
1050	Imaging tumor angiogenesis: functional assessment using MDCT or MRI?. 2006 , 31, 194-9	64
1049	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. 2006 , 55, 958-68	116
1048	Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. 2006 , 55, 1209-18	100
1047	Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. 2006 , 29, 522-9	186

1046	Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. 2006 , 57, 46-51	15
1045	Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. 2006 , 57, 282-8	30
1044	Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer. 2006 , 58, 86-90	11
1043	A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer. 2006 , 57, 755-60	5
1042	A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. 2006 , 57, 789-95	34
1041	Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer. 2006 , 58, 266-71	2
1040	Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. 2006 , 58, 419-26	4
1039	A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial. 2006 , 58, 368-73	15
1038	Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. 2006 , 58, 527-31	5
1037	A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. 2006 , 58, 703-10	7
1036	Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial. 2006 , 58, 555-60	5
1035	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. 2006 , 58, 585-93	10
1034	A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. 2006 , 58, 759-64	116
1033	Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. 2007 , 59, 1-7	12
1032	Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. 2007 , 59, 285-93	26
1031	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). 2007 , 59, 295-300	13
1030	Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. 2007 , 59, 361-7	20
1029	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. 2006 , 8, 193-9	13

1028	Feasibility study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function. 2006 , 8, 755-7	18
1027	Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. 2006 , 7, 16-22	9
1026	Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. 2006 , 20, 115-21	62
1025	A phase II study of irifolven in women with recurrent and heavily pretreated ovarian cancer. 2006 , 101, 55-61	26
1024	Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study. 2006 , 101, 114-9	4
1023	Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. 2006 , 101, 464-9	136
1022	Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. 2006 , 102, 49-53	21
1021	CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. 2006 , 103, 212-8	18
1020	Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. 2006 , 103, 439-45	10
1019	Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. 2006 , 103, 489-93	70
1018	Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. 2006 , 103, 919-23	15
1017	The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. 2006 , 103, 1083-90	256
1016	Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. 2006 , 49, 76-81	27
1015	Segmentation of brain tumors in 4D MR images using the hidden Markov model. 2006 , 84, 76-85	22
1014	DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. 2006 , 1766, 197-204	12
1013	Assessing responses to cancer therapy using molecular imaging. 2006 , 1766, 242-61	45
1012	A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. 2006 , 6, 121	16
1011	Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). 2006 , 6, 122	28

1010	Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. 2006 , 6, 125	30
1009	Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. 2006 , 6, 129	97
1008	A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. 2006 , 6, 535-9	39
1007	Clinical utility of measuring circulating tumor cells in metastatic breast cancer. 2006 , 7, 85-6	1
1006	Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. 2006 , 7, 141-5	12
1005	Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. 2006 , 7, 326-30	18
1004	Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. 2006 , 4, 275-80	11
1003	Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. 2006 , 7, 401-5	16
1002	Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. 2006 , 7, 406-11	31
1001	Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer. 2006 , 8, 208-13	4
1000	Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. 2006 , 93, 587-92	39
999	Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. 2006 , 93, 1001-6	62
998	Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. 2006 , 106, 106-11	36
997	The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. 2006 , 106, 297-303	63
996	Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. 2006 , 106, 375-82	93
995	Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. 2006 , 106, 366-74	44
994	Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. 2006 , 106, 514-23	114
993	Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. 2006 , 106, 566-75	50

992	Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. 2006 , 106, 890-9	42
991	Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. 2006 , 106, 1347-52	81
990	Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. 2006 , 106, 2005-11	258
989	Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. 2006 , 106, 2421-7	42
988	Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. 2006 , 106, 2445-51	39
987	Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. 2006 , 107, 83-9	120
986	A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. 2006 , 107, 319-27	27
985	Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. 2006 , 107, 599-605	22
984	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. 2006 , 107, 1034-41	69
983	A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. 2006 , 107, 1273-9	60
982	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. 2006 , 107, 1866-72	3
981	Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). 2006 , 107, 1883-90	52
980	Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. 2006 , 107, 2254-61	35
979	Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. 2006 , 107, 2482-9	44
978	A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. 2006 , 107, 2688-97	50
977	Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. 2006 , 107, 2609-16	52
976	Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. 2006 , 107, 2462-7	73
975	Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. 2006 , 107, 2881-7	56

974	Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. 2006 , 44, 1518-27	115
973	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. 2006 , 118, 963-9	130
972	Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. 2006 , 119, 406-13	64
971	SET complex in serous epithelial ovarian cancer. 2006 , 119, 2119-26	50
970	Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. 2006 , 119, 2428-34	70
969	Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. 2006 , 12, 1260-7	319
968	Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number?. 2006 , 12, 1189-91	16
967	Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. 2006 , 93, 401-9	24
966	Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. 2006 , 23, 554-63	131
965	Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?. 2006 , 1, 684-691	11
964	Pathotropic nanoparticles for cancer gene therapy Rexin-G IV : Three-year clinical experience. 2006 , 29, 1053	3
963	Using immunotherapy to target EGF in patients with NSCLC. 2006 , 5, 150-1	1
962	Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. 2006 , 70, 154-8	27
961	A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer. 2006 , 70, 330-8	2
960	A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors. 2006 , 71, 347-53	
959	A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. 2006 , 71, 369-73	22
958	Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients. 2006 , 70, 325-9	30
957	Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. 2006 , 12, 1229-36	58

956	Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. 2006 , 24, 1428-34	129
955	CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. 2006 , 186, 1067-70	34
954	Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. 2006 , 91, 2201-4	49
953	Polyp volume versus linear size measurements at CT colonography: implications for noninvasive surveillance of unresected colorectal lesions. 2006 , 186, 1605-10	35
952	Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. 2006 , 239, 730-9	31
951	Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. 2006 , 187, 164-9	66
950	Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. 2006 , 17, 409-14	79
949	Wertigkeit der Magnetresonanztomographie (MRT) des Beckens in der Stadieneinteilung, Verlaufskontrolle und Rezidivdiagnostik des Zervixkarzinoms. 2006 , 66, 1177-1185	
948	Are prostate cancer clinical trial enrollment criteria and endpoints appropriate?. 2006 , 3, 74-5	2
947	Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. 2006 , 114, 361-5	24
946	Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. 2006 , 17, 1592-7	40
945	Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg. 2006 , 24, 207-11	3
944	Inherent variability of CT lung nodule measurements in vivo using semiautomated volumetric measurements. 2006 , 186, 989-94	115
943	Zur Qualitätssicherung von Einzelfallberichten und Fallserien in der Onkologie. 2006 , 38, 62-65	
942	Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage?. 2006 , 187, 1079-84	68
941	Evolving role of serum biomarkers in the management of ovarian cancer. 2006 , 2, 141-58	4
940	Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility?. 2006 , 79, 578-83	27
939	Variability in mesothelioma tumor response classification. 2006 , 186, 1000-6	38

938	Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques. 2006 , 3, 315-24	48
937	Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. 2006 , 239, 547-53	123
936	Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. 2006 , 36, 93-9	19
935	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. 2006 , 12, 6049-55	173
934	A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. 2006 , 24, 382-9	4
933	Phase II clinical trials in oncology: strengths and limitations of two-stage designs. 2006 , 24, 404-12	14
932	Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). 2006 , 17, 952-6	82
931	A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. 2006 , 17, 1826-9	58
930	Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. 2006 , 24, 45-51	85
929	Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. 2006 , 24, 1831-8	202
928	Gene Expression Profiling of Epithelial Ovarian Cancer. 2006 , 7, 115-135	3
927	Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. 2006 , 24, 4092-9	170
926	Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. 2006 , 24, 5448-53	194
925	A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. 2006 , 17, 429-36	25
924	A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. 2006 , 5, 766-70	91
923	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. 2006 , 17, 467-72	106
922	Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. 2006 , 17, 813-7	99
921	Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. 2006 , 24, 1807-13	134

920	Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. 2006 , 24, 1898-903	332
919	Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. 2006 , 24, 1052-6	112
918	Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer. 2006 , 36, 218-23	9
917	Powerful prognostic stratification by [¹⁸ F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. 2006 , 24, 3026-31	76
916	A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. 2006 , 12, 2841-8	6
915	Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. 2006 , 45, 890-6	63
914	Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. 2006 , 17, 563-70	342
913	Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. 2006 , 36, 704-11	19
912	Stereotactic Body Radiation Therapy (SBRT) for lung metastases. 2006 , 45, 808-17	190
911	Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. 2006 , 26, 481-95	152
910	Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. 2006 , 24, 1712-9	55
909	A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. 2006 , 36, 410-7	23
908	Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. 2006 , 36, 17-24	31
907	Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. 2006 , 12, 3078-84	85
906	Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. 2006 , 13, 1195-202	81
905	A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. 2006 , 12, 4274-82	28
904	Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. 2006 , 24, 5201-6	362
903	Measures of response: RECIST, WHO, and new alternatives. 2006 , 24, 3245-51	243

902	Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. 2006 , 17, 968-73	53
901	Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. 2006 , 24, 2084-91	38
900	Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. 2006 , 12, 6116-24	127
899	Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. 2006 , 24, 4848-54	28
898	Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. 2006 , 177, 6548-59	250
897	Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. 2006 , 17, 443-9	26
896	Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. 2006 , 24, 1883-91	122
895	Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. 2006 , 17, 334-40	85
894	DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. 2006 , 24, 4333-9	116
893	Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. 2006 , 12, 139-43	27
892	Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. 2006 , 24, 4825-32	56
891	Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. 2006 , 12, 3124-9	108
890	Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. 2006 , 12, 1270-5	46
889	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. 2006 , 17, 450-6	185
888	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. 2007 , 29, 128-33	11
887	Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. 2006 , 24, 2252-60	122
886	Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. 2006 , 5, 2914-8	103
885	A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. 2006 , 17, 1128-33	34

884	In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. 2006 , 12, 5454-63		74
883	Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. 2006 , 12, 3402-7		137
882	A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. 2006 , 17, 1399-403		107
881	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. 2006 , 12, 6064-72		215
880	Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 580-98	9.7	167
879	Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. 2006 , 12, 507-15		70
878	Sunitinib in patients with metastatic renal cell carcinoma. 2006 , 295, 2516-24		968
877	Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. 2006 , 24, 1892-7		81
876	A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. 2006 , 12, 1237-44		31
875	Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. 2006 , 71, 320-6		29
874	ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. 2006 , 12, 7149-58		81
873	Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. 2006 , 24, 4558-64		7
872	Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. 2006 , 24, 769-77		459
871	Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. 2006 , 12, 5777-85		191
870	Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. 2006 , 24, 3013-8		56
869	Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. 2006 , 24, 4069-77		89
868	The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. 2006 , 12, 2834-40		73
867	Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. 2006 , 66, 10136-44		55

866	Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. 2006 , 24, 4738-45	514
865	Lung cancer: computerized quantification of tumor response--initial results. 2006 , 241, 892-8	97
864	A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. 2006 , 17, 1313-9	17
863	Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. 2006 , 24, 1705-11	196
862	Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. 2006 , 24, 4840-7	70
861	A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. 2006 , 17, 663-7	56
860	Dual energy CT attenuation correction methods for quantitative assessment of response to cancer therapy with PET/CT imaging. 2006 , 5, 319-27	44
859	Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. 2006 , 24, 4587-93	134
858	Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. 2006 , 12, 144-51	170
857	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. 2006 , 12, 3908-14	479
856	Methodology of clinical trials with new molecular-targeted agents: where do we stand?. 2006 , 17 Suppl 7, vii128-31	21
855	Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. 2006 , 24, 3007-12	33
854	Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. 2006 , 17, 252-8	26
853	Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. 2006 , 8, 38-46	141
852	RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. 2006 , 24, 4731-7	286
851	Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. 2006 , 24, 1839-45	129
850	Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. 2006 , 24, 2793-9	298
849	Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. 2006 , 8, 156-65	101

848	PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. 2006 , 5, 37-43	47
847	Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. 2006 , 24, 500-6	148
846	Adverse event reporting in publications compared with sponsor database for cancer clinical trials. 2006 , 24, 3933-8	77
845	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. 2006 , 24, 4914-21	45 ^o
844	Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. 2006 , 12, 1585-92	194
843	Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. 2006 , 12, 3774-81	12
842	A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. 2006 , 12, 5471-80	84
841	YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. 2006 , 12, 5698-704	137
840	Pharmacogenetics of capecitabine in advanced breast cancer patients. 2006 , 12, 5496-502	91
839	A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. 2006 , 12, 7039-45	99
838	Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. 2006 , 36, 552-6	26
837	A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). 2006 , 17, 1007-13	82
836	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. 2006 , 17, 1120-7	75
835	Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. 2006 , 17 Suppl 7, vii68-72	44
834	CT and MRI of Lung Cancer. 2006 , 73, 133-42	27
833	Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. 2006 , 17, 1529-32	13
832	FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 2006 , 17 Suppl 7, vii55-9	18
831	Targeting von Hippel-Lindau syndrome: the future is now. 2006 , 2, 321-3	

830	Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. 2006 , 24, 3354-60	158
829	Lapatinib plus capecitabine for HER2-positive advanced breast cancer. 2006 , 355, 2733-43	2641
828	Irinotecan for children with relapsed solid tumors. 2006 , 23, 103-10	19
827	Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia. 2006 , 5, 211-22	3
826	Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. 2007 , 34, 25-36	23
825	A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFCEP1 and a bis-iodo phenol mustard prodrug. 2006 , 12, 6509-16	64
824	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. 2006 , 24, 4922-7	269
823	Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. 2006 , 24, 5247-52	35
822	Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. 2006 , 12, 6437-43	53
821	Les cancers ovariens. 2006 ,	
820	Phase II study of erlotinib in patients with advanced biliary cancer. 2006 , 24, 3069-74	261
819	Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. 2006 , 5, 717-32	21
818	Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. 2006 , 94, 1402-6	24
817	Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. 2006 , 3, 658-67	50
816	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. 2006 , 95, 1148-54	272
815	Molecular imaging in the development of cancer therapeutics. 2006 , 57, 99-118	96
814	Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. 2006 , 94, 1407-11	25
813	Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. 2006 , 94, 1803-8	57

812	Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. 2006 , 94, 481-5	108
811	Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. 2006 , 16, 801-10	17
810	A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. 2006 , 21, 561-8	22
809	Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. 2006 , 24, 4384-90	53
808	Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. 2006 , 24, 3678-85	79
807	Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. 2006 , 66, 4943-51	96
806	EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. 2006 , 8, 137-44	68
805	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. 2006 , 12, 3915-21	265
804	Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. 2006 , 24, 3939-45	463
803	Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. 2006 , 24, 1612-9	181
802	Relationship between cisplatin administration and the development of ototoxicity. 2006 , 24, 918-24	118
801	Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. 2006 , 24, 2276-82	231
800	CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. 2006 , 17, 1234-8	71
799	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. 2007 , 12, 426-37	352
798	Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. 2007 , 13, 6130-5	22
797	Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. 2007 , 18, 88-92	27
796	Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. 2007 , 37, 897-906	48
795	A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. 2007 , 6, 840-5	10

794	Phase I trial of imexon in patients with advanced malignancy. 2007 , 25, 1779-84	49
793	Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. 2007 , 13, 5398-405	100
792	Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. 2007 , 25, 4880-6	53
791	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. 2007 , 25, 3936-44	105
790	A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. 2007 , 13, 3276-85	137
789	Transcatheter and ablative therapeutic approaches for solid malignancies. 2007 , 25, 978-86	148
788	Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. 2007 , 67, 11991-9	172
787	We should desist using RECIST, at least in GIST. 2007 , 25, 1760-4	450
786	Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. 2007 , 37, 30-7	34
785	A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. 2007 , 30, 169-74	8
784	Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. 2007 , 13, 770s-776s	102
783	Cancer vaccines: moving beyond current paradigms. 2007 , 13, 3776-82	186
782	Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. 2007 , 13, 972-6	56
781	Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. 2007 , 13, 584-90	43
780	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. 2007 , 25, 5225-32	273
779	Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 628-38	9.7 624
778	Treatment options in renal cell carcinoma: past, present and future. 2007 , 18 Suppl 10, x25-31	49
777	Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. 2007 , 48, 1592-8	99

776	Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. 2007 , 25, 3055-60	55
775	Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. 2007 , 25, 2727-34	85
774	Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. 2007 , 25, 4562-8	195
773	The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. 2007 , 6, 1180-5	32
772	Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. 2007 , 13, 1208-15	58
771	Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. 2007 , 13, 6175-81	78
770	Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. 2007 , 25, 1512-8	38
769	A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. 2007 , 96, 1633-43	23
768	Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. 2007 , 96, 21-8	22
767	Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. 2007 , 96, 38-43	10
766	Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. 2007 , 97, 862-7	71
765	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. 2007 , 97, 1469-74	64
764	Widespread functional and molecular imaging in drug development. 2007 , 2, 1477-85	4
763	Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. 2007 , 25, 3978-84	200
762	Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. 2007 , 25, 669-74	254
761	Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. 2007 , 356, 2271-81	3025
760	A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. 2007 , 97, 1338-43	56
759	Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. 2007 , 96, 439-44	33

758	Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007 , 26, 375-386	12
757	Response evaluation: beyond RECIST. 2007 , 18 Suppl 9, ix29-32	23
756	Breast lymphoma: imaging findings of 32 tumors in 27 patients. 2007 , 245, 692-702	102
755	Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. 2007 , 12, 1134-42	116
754	Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer. 2007 , 37, 175-80	4
753	Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. 2007 , 18, 1673-9	105
752	Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. 2007 , 25, 1747-52	93
751	Monitoring Responses to Therapy in Oncology. 2014 , 155-171	
750	Imaging Review Charters and Operational Considerations. 2014 , 65-82	
749	Bone Metastasis. 2014 , 1389-1410	
748	MUC16, alias CA125 and ovarian cancer. 2013 , 82-93	
747	Aspects post-thérapeutiques des carcinomes hépatocellulaires. 2014 , 137-166	
746	Bildgebende Diagnostik von ossären Metastasen. 2014 , 33-47	
745	Defining Clinical Endpoints in Castration-Resistant Prostate Cancer. 2014 , 187-199	
744	Three Cases of Advanced Gastric Cancer Confirmed as pathological Complete Response following Neoadjuvant Chemotherapy and Gastric Resection. 2014 , 75, 2188-2193	1
743	Hepatic metastases. 2014 , 80-92	
742	Application of the Stable Isotope Breath Test for Digestive Disease Diagnosis and Therapeutic Effect. 2014 , 63, 567-584	
741	2-13C-Uracil ?????????S-1 ??????. 2014 , 73, 50-55	

- 740 Salvage Treatment with Low-Dose Weekly Paclitaxel in Elderly or Poor Performance Status Patients with Metastatic Urothelial Carcinoma. **2014**, 100, 439-445
- 739 Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies. **2014**, 155-165
- 738 Multicenter Analysis of mFOLFOX6 with Oxaliplatin Stop-and-Go Strategy Using Oral Uracil-Tegafur with Leucovorin for Unresectable Colorectal Cancer in Elderly Patients. **2014**, 05, 147-154 1
- 737 Epirubicin/Cyclophosphamide followed by Docetaxel as Primary Systemic Therapy in Breast Cancer. **2014**, 22, 19-23
- 736 Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate. **2014**, 71, 239
- 735 Advanced Thyroid Cancer Patients in Phase I Clinical Trials: Outcome Assessment and Literature Review. **2014**, 5, 24-32
- 734 Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes. **2014**, 15, 1061-2
- 733 Phase III Targeted Treatments. **2014**, 177-186
- 732 Chemotherapy (Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin) in Elderly Patients with Non-Small Cell Lung Cancer. **2014**, 05, 281-296 1
- 731 Significant Symptom Relief with Hepatic Artery Embolization in a VIPoma with Liver Metastases. **2014**, 87, 363
- 730 Complete response induced by half dose of sorafenib administration in advanced hepatocellular carcinoma with peritoneal dissemination. **2014**, 55, 100-105 1
- 729 Role of Combination Chemotherapy with 5-Fluorouracil, Cisplatin and Paclitaxel for Advanced Gall Bladder Cancer. **2014**, 05, 246-252 1
- 728 Feasibility Study of Synchronized Intra-aortic Chemotherapy for Stage IV and Recurrent Gastric Cancer Localized in the Abdominal Cavity. **2014**, 22, 12-18
- 727 Hepatoblastoma Survival and the Prognostic Role of Cancer Stem Cell Markers. **2014**, 2,
- 726 Clinical study on the sensitivity test guided hepato-arterial/portal-vein chemotherapy in patients with unresectable hepatocellular carcinoma. **2014**, 2, 02029
- 725 Response to chemotherapy and association with three tumour markers in breast cancer patients in Ghana. **2014**, 2, 02034
- 724 Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. **2014**, 3, 175-8 1
- 723 Ifosfamide-containing regimens for treating patients with osteosarcomas. **2014**, 15, 9763-6 2

722 Angiogenesis Inhibitor Therapy in Renal Cell Cancer. **2015**, 281-294

721 Chemoenzymatic Synthesis of an Enantiomerically Enriched Bicyclic Carbocycle Using *Candida parapsilosis* ATCC 7330 Mediated Enantioselective Hydrolysis. **2015**, 05, 271-281

720 Hirntumoren im Kindesalter. **2015**, L6a.1-L6a.10

719 Post-locoregional Therapy Imaging of the Liver. **2015**, 97-109

718 Fixed Dose Rate versus Standard Dose Rate Infusion of Gemcitabine and Cisplatin in Advanced Stage Non-Small Cell Lung Cancer. **2015**, 06, 45-52

717 Immunogenic Cell Death Markers in Liver Cancer. **2015**, 303-324

716 Phase I Trials Today. **2015**, 661-676.e2

715 MAID (Mesna, Adriamycin, Ifosfamide, Dacarbazine) Combination Chemotherapy in a Patient with Angiosarcoma of the Skin. **2015**, 64, 199-203

714 Encyclopedia of Cancer. **2015**, 1-5

713 Stadieneinteilung endokriner Tumore. **2015**, 255-266

712 Post-therapy Surveillance of Bone Tumors. **2015**, 211-219

711 Investigation into the Appropriate Post-neoadjuvant Chemotherapy Hepatectomy Margin to Include Both Macro- and Micrometastasis from Colorectal Carcinoma. **2015**, 6, 195-204

710 A Multicenter Cohort Study for XELOX (Capecitabine, Leucovorin plus Oxaliplatin) Therapy as First-Line Treatment in Elderly Patients with Unresectable Colorectal Cancer. **2015**, 06, 153-162

709 Evaluation of Response in Malignant Tumors Treated with Targeted Agents. **2015**, 43-55

708 Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation. **2015**, 06, 1214-1222

707 Efficacy of 5-Fluorouracil and High-Concentration Cisplatin Suspended in Lipiodol by Short-Term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. **2015**, 06, 1151-1161

706 Bone Metastases. **2015**, 867-889

705 Onkologische Bildgebung zur Beurteilung des Therapieansprechens. **2015**, 91-100

- 704 Efficacy and Safety of Fixed-Dose-Rate Infusions of Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer. **2015**, 4, 44-51
- 703 Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. **2015**, 16, 2391-5 3
- 702 Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. **2015**, 16, 4127-31 2
- 701 Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung. **2015**, 6, 14-18 1
- 700 Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil. **2015**, 16, 5289-96
- 699 Evaluation of Magnetic Resonance Imaging Findings and Short-Term Outcome in Brain Metastatic Tumors after CyberKnife Treatment. **2016**, 05, 96-99
- 698 Diagnostic Applications of Nuclear Medicine: Pediatric Cancers. **2016**, 1-35
- 697 RECIST. **2016**, 572-575
- 696 The Existence of Symptomatic Localized Lesion(s) and ≥ 4 Lesions Are Indications for Radiotherapy: Screening Computed Tomography Images of Patients with Metastatic/Recurrent/Inoperable Cancer in a Single Japanese Institution Observational Study. **2016**, 05, 110-119
- 695 Diagnostic Applications of Nuclear Medicine: Gastrointestinal Stromal Tumors. **2016**, 1-15
- 694 Lung. **2016**, 109-144
- 693 The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study. **2016**, 07, 297-302
- 692 Diagnostic Applications of Nuclear Medicine: Tumors of the Liver and Biliary Tract. **2016**, 1-23
- 691 Follow-up of multicentric HCC according to the mRECIST criteria: role of 320-Row CT with semi-automatic 3D analysis software for evaluating the response to systemic therapy. **2017**, 37, 206-210
- 690 International Network for Sharing Practices on Electrochemotherapy (InspECT): An Integrative Patients Treatment Consortium. **2016**, 1-18
- 689 Phase I Study to Determine the Starting Dose for Estimating the Individualized Maximum Repeatable Dose in Tumor Dormancy Therapy with Weekly Paclitaxel for Recurrent and Metastatic Head and Neck Cancer. **2016**, 109, 883-888
- 688 Encyclopedia of Cancer. **2016**, 3880-3883
- 687 Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer. **2016**, 337-348

686 Novel Translational Research of Neo-adjuvant Endocrine Therapy. **2016**, 189-216

685 Design, Implementation, and Interpretation of Clinical Trials. **2016**, 601-635

684 Lung and Mediastinal Tumors. **2016**, 1-46

683 Hapten Improved Overall Survival Benefit in Late Stages of Non-Small Cell Lung Cancer (NSCLC) by Ultra-Minimum Incision Personalized Intratumoral Chemo Immunotherapy (UMIPIC) Therapy With and without Radiation Therapy. **2016**, 4,

682 Imaging Biomarker Measurements. **2017**, 87-99

1

681 Basics and Advances of Quantitative PET Imaging. **2017**, 303-322

1

680 Multimodality Therapy for Metastatic Gastrointestinal Stromal Tumor. **2017**, 187-208

679 Microwave ablation and irreversible electroporation. **2017**, 1448-1458.e2

678 Diagnostic Applications of Nuclear Medicine: Gastrointestinal Stromal Tumors. **2017**, 709-723

677 International Network for Sharing Practices on Electrochemotherapy (InspECT): An Integrative Patients Treatment Consortium. **2017**, 1799-1816

1

676 Diagnostic Applications of Nuclear Medicine: Pediatric Cancers. **2017**, 1103-1137

675 Management of Hepatocellular Carcinoma Patients with Portal Vein Thrombosis Using Three-Dimensional Conformal Radiotherapy. **2017**, 08, 579-590

674 Irreversible Electroporation Techniques in the Treatment of Locally Advanced Liver and Pancreatic Cancer. **2017**, 1-16

673 Magnetic Resonance Imaging and Neoadjuvant Chemotherapy. **2017**, 103-120

672 Stereotactic body radiation therapy for early-stage primary lung cancer, is an active breath coordinator necessary? An audit from a tertiary cancer care center. **2017**, 54, 301-304

671 Is It Reasonable for Orthopedic Surgeons to Do Chemotherapy for Patients with High-Grade Bone Sarcoma? A Paradigm for Treatment Individualization. **2017**, 561-571

670 Hepatic Arterial Infusion Chemotherapy with Cisplatin for TACE-Refractory or -Ineligible Hepatocellular Carcinoma with Child-Pugh Score of 8 or Above. **2017**, 17,

669 Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. **2017**, 117-131

- 668 Diagnostic Applications of Nuclear Medicine: Tumors of the Liver and Biliary Tract. **2017**, 725-747
- 667 Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma. **2017**, 105-116
- 666 Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors. **2017**, 639-684
- 665 Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors. **2017**, 1-46
- 664 On the relationship between tumour growth rate and survival in non-small cell lung cancer.
- 663 CT-guided I brachytherapy for recurrent ovarian cancer. **2017**, 8, 59766-59776 3
- 662 COMPARISON OF WHO AND RECIST RESPONSE CRITERIA IN LOCALLY ADVANCED BREAST CANCER: A DESCRIPTIVE STUDY. **2017**, 6, 4695-4698
- 661 Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed. **2017**, 8, 74910-74916
- 660 Treatment response assessment and response guided adaptive treatment. **2017**, 337-350
- 659 REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE. **2017**, 30-38 1
- 658 Treatment Response Evaluation in Hepatic Tumors using CT and MRI: Road Map for Radiologist. **2017**, 49-62
- 657 Estimability index for volume quantification of homogeneous spherical lesions in computed tomography. **2018**, 5, 031404 2
- 656 Combined radiotherapy for cervical cancer with the use of polyradiosensitization with cisplatin and gemcitabine - immediate trial results of Azerbaijan national center of oncology. **2017**, 98, 884-889
- 655 High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review. **2018**, 5, 183-241 2
- 654 Rare Tumors in Pediatric Oncology. **2018**, 131-170
- 653 Stadieneinteilung endokriner Tumore. **2018**, 289-300
- 652 Integration of Genomic and Transcriptomic Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.
- 651 Liver-Directed Therapies for Neuroendocrine Metastases. **2018**, 255-265

650 Konzepte klinischer Studien. **2018**, 257-263

649 Multiple Endocrine Neoplasia Type 2. 1-8

648 Basic Study of the Imaging Conditions on Tumor Volume Measurement Using 3D-MR Imaging of the Liver While Patient Holds Breath. **2019**, 29-33

647 Clinical outcome of stereotactic ablative radiotherapy with CyberKnife® for lung tumors: a single center experience.

646 Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia. **2018**, 34-40

645 A case of advanced hepatocellular carcinoma treated successfully with Juzentaihoto. **2018**, 59, 355-362

644 Anti-angiogenics in Kidney Cancer Therapy. **2019**, 1-10

643 Interchangeability between real and three-dimensional simulated lung tumors in computed tomography: an interalgorithm volumetry study. **2018**, 5, 035504

2

642 Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients. **2018**, 20, 19-25

641 The role of immunotherapy in the treatment of non-small cell lung cancer. **2018**, 12, 185-193

640 Impact of topoisomerase II β overexpression in the primary colon tumor on the prognosis of metastatic colorectal cancer. **2018**, 8, 26-35

1

639 Therapeutic Evaluation of Radiotherapy with Contrast-Enhanced Ultrasound in Non-Resectable Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. **2018**, 24, 8183-8189

1

638 Addition of bevacizumab to adjuvant chemotherapy paclitaxel and carboplatin for cancer ovary. is there a difference?. **2018**, 9,

637 Measuring Malignant Pleural Mesothelioma. **2019**, 153-166

636 Allgemeines. **2019**, 1-43

635 The Impact of Neutrophil to Lymphocytic Ratio (NLR) as a Predictor of Treatment Outcomes in Rectal Carcinomas: A Retrospective Cohort Study. **2019**, 10, 755-777

634 Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer. **2019**, 97, 93-102

0

633 Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer.

- 632 Prognostic Factors in Geriatric Patients with Metastatic Colon Cancer. **2019**, 10, 779-788
- 631 Anti-angiogenics in Kidney Cancer Therapy. **2019**, 569-578
- 630 What is the Current Effectiveness of Olaparib for Breast Cancer Patients with a BRCA Mutation? A Systematic Review. **2019**, 13, 39-59
- 629 Long-term survival of a patient with pancreatic ductal adenocarcinoma with peritoneal dissemination treated with S-1 plus intravenous and intraperitoneal paclitaxel followed by conversion surgery. **2019**, 34, 1-8
- 628 Radioterapia neoadyuvante e intraoperatoria en sarcoma de muslo y regi3n popl3nea para salvamento de extremidad. Reporte de caso y revisi3n de la literatura. **2019**, 23, 28-34
- 627 Stereotaktik radyocerrahi uygulanan vertebra metastazlar3nda yan3t de3erlendirmesinde PET-BT3in yeri. 44, 1-10
- 626 Criteria for Evaluation of Clinical Efficacy of Anticancer Medicines. **2019**, 9, 34-40 1
- 625 The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. 1
- 624 Prognostic value of Bax expression in the primary colon tumor of patients with metastatic colorectal cancer receiving first-line treatment with a triple combination of irinotecan + oxaliplatin + long-term infusion of 5-fluorouracil. **2019**, 9, 51-59
- 623 Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. **2019**, 7, 253 1
- 622 Multidisciplinary Treatment of Liver Metastasis from Colorectal Cancer to Create Novel Evidences. **2019**, 52, 390-403
- 621 Immunotherapy. **2020**, 237-269
- 620 Radiology. **2020**, 87-117
- 619 Serviks Kanserinde Prognostik Kriterlerin Tedavi Sonras3 Erken Radyolojik Cevaba Etkisi.
- 618 The Management of Hepatocellular Carcinoma. **2020**, 237-271 0
- 617 Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence Patterns.
- 616 Dose-Response to Different Radiochemotherapy Regimens in Locally Advanced Pancreatic Cancer. **2020**, 1276-1282 1
- 615 Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. **2019**, 11, 447-454 3

- 614 An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with mutation and tumor sidedness.. **2019**, 8, 2357-2370
- 613 Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis. **2020**, 19, 261-270
- 612 Immunotherapy and Gliomas. **2020**, 251-265
- 611 Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia. **2019**, 104-113 1
- 610 Opportunities and limitations of CT - assessment of neoadjuvant chemoradiation therapy of gastric cancer. **2019**, 6, 92-101
- 609 Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) + Leucovorin in patients with advanced colorectal cancer. **2019**, 92-102
- 608 Chemoembolization for Colorectal Liver Metastases. **2020**, 507-518
- 607 Diagnosis and Management of Benign Nerve Sheath Tumors in NF1: Evolution from Plexiform to Atypical Neurofibroma and Novel Treatment Approaches. **2020**, 165-179
- 606 Computed Tomography and Magnetic Resonance Imaging. **2020**, 216, 31-110
- 605 Imaging Findings Following Locoregional Cancer Therapies. **2020**, 329-370
- 604 Does a 6-point scale approach to post-treatment 18F-FDG PET-CT allow to improve response assessment in head and neck squamous cell carcinoma? A multicenter study. **2020**, 4, 8 0
- 603 Correlation of clinico-pathologic data with inflammatory cells infiltration in colorectal cancer. **2020**, 10, 69-76
- 602 Systemic inflammation markers in blood samples of colorectal cancer patients. **2020**, 10, 92-101
- 601 Predicting clinical drug response from model systems by non-linear subspace-based transfer learning. 2
- 600 Integration of machine learning and genome-scale metabolic modeling identifies multi-omics biomarkers for radiation resistance. 0
- 599 The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment. **2021**, 2, e103 0
- 598 Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. **2021**, 75, 942 1
- 597 Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period. 1-8 1

- 596 The Therapeutic Principle of Combined Strengthening Qi and Eliminating Pathogens in Treating Middle-Advanced Primary Liver Cancer: A Systematic Review and Meta-Analysis. **2021**, 12, 714287 1
- 595 Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer. Hyperthermia versus Normothermia. A randomized controlled trial.
- 594 Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature. **2021**, 13, 1
- 593 Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. **2021**, 13, 1
- 592 Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy. **2021**, 13, 1
- 591 A Serum Proteomic Signature Predicting Survival in Patients with Glioblastoma. **2020**, 4,
- 590 Response Assessment and Follow-Up by Imaging in GYN Tumours. **2020**, 517-530
- 589 Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. **2020**, 27, e537-e546 1
- 588 S-1 Plus Leucovorin and Oxaliplatin in Combination with Lentinan as First-line Therapy in Patients with Metastatic Gastric Cancer. 9, 69-74
- 587 STUDY OF CHANGES IN TUMOR BLOOD FLOW FOR THE ASSESSMENT OF EARLY RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS. **2020**, 19, 46-56
- 586 Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. **2020**, 8, 1589
- 585 Toward radiomics for assessment of response to systemic therapies in lung cancer. **2020**, 11, 4677-4680 0
- 584 Efficacy of Chinese herbal injections combined with fluoropyrimidine and oxaliplatin-based chemotherapy for advanced colorectal cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. **2020**, 99, e23550 2
- 583 Magnetic resonance imaging (MRI) in staging and restaging after neoadjuvant therapy. **2022**, 131-147
- 582 Incorporating Circulating Biomarkers into Clinical Trials. **2020**, 233-247
- 581 Response Evaluations for Precision Cancer Therapy and Immunotherapy. **2020**, 15-27
- 580 Tumor-infiltrating lymphocytes in primary tumors of colorectal cancer and their metastases. **2019**, 18, 4904-4912 2
- 579 Evolution of Clinical Trial Imaging and Co-clinical Imaging. **2020**, 239-253

- 578 Intensity-modulated Radiation Therapy for Lymph Node Oligo-recurrence. **2020**, 34, 2587-2593 2
- 577 Therapy Response Imaging in Hepatobiliary and Pancreatic Malignancies. **2020**, 117-137
- 576 Functional Imaging in Hodgkin Lymphoma. **2020**, 113-143
- 575 Response Assessment and Follow-Up by Imaging in Breast Tumors. **2020**, 451-474
- 574 The promising role of mucin 4 in association with D2-40 immunohistochemistry in differentiating pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. **2020**, 40, 237
- 573 Efficacy and Safety of Capecitabine Metronomic Chemotherapy versus Conventional Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer.
- 572 Advanced Ultrasound Imaging for Patients in Oncology: DCE-US. **2020**, 216, 765-771 1
- 571 Assessment of Tumor Response with MRI and CT After Radioembolization. **2020**, 1001-1009
- 570 Conventional Tumor Response Criteria and Limitations. **2020**, 3-14
- 569 Response Assessment and Follow-Up by Imaging in Lung Tumours. **2020**, 417-449
- 568 Use of the Hedgehog signaling pathway inhibitor in the treatment of recurrent locally advanced and metastatic basal cell skin cancer. **2020**, 9, 38-42
- 567 Chemotherapy for breast cancer progresses to liver metastases after surgery and systemic treatment.. **2020**, 9, 993-1000 1
- 566 Early Imaging Marker of Progressive Glioblastoma: a window of opportunity
- 565 Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis. **2021**, 21, 1173 1
- 564 Efficacy and Safety of Interferon-Alpha 2b for Patients with Hepatic Epithelioid Hemangioendothelioma: Outcomes of a Case-Series Analysis. **2021**, 13, 8273-8279 0
- 563 Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide. **2021**, 11, 11, 1
- 562 Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial. **2020**, 165-174 1
- 561 Valutazione della risposta al trattamento medico antitumorale delle metastasi epatiche. **2007**, 93-94

560 Ecografia e oncologia. **2007**, 1-25

559 Clinical trial design and regulatory issues for therapeutic cancer vaccines. **2005**, 123, 351-68

558 Therapy for Malignant Pleural Mesothelioma. **2006**, 629-651

557 Imaging of Lung Cancer. **2006**, 57-78

556 PET and PET/CT Imaging in Esophageal and Gastric Cancers. **2006**, 165-180

555 La chimiothérapie des rechutes au-delà de six mois. **2006**, 417-425

554 Pitfalls in the Design, Conduct and Analysis of Randomised Clinical Trials. **2005**, 495-503

553 Klinische Studien: Planung, Durchführung und Interpretation. **2006**, 634-644

552 MDCT Imaging of Focal Lung Disease. **2006**, 155-173

551 Statistische Bewertung von Therapieergebnissen. **2006**, 311-322

550 The Role of Chemotherapy in the Management of Mesothelioma. **2006**, 515-524

549 Neck Lymphoma. **2008**, 311-328

548 Clinical drug evaluation using imaging readouts: regulatory perspectives. **2005**, 62, 357-84

0

547 A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). **2006**, 24, 343

546 Dendritic Cell Vaccines. **2007**, 251-274

545 Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. **2008**, 307-316

1

544 New Tumor Biomarkers. **2008**, 189-207

0

543 Endpoints for the Determination of Efficacy of Antiangiogenic Agents in Clinical Trials. **2008**, 509-524

1

- 542 Anatomical Measure of Tumor Growth with Computed Tomography and Magnetic Resonance Imaging. **2007**, 33-46 1
- 541 [18F]Fluorodeoxyglucose Positron Emission Tomography Assessment of Response. **2007**, 103-120 1
- 540 Measurement of Tumor Proliferation with Positron Emission Tomography and Treatment Response. **2007**, 121-142
- 539 Drug Development in Cancer Medicine: Challenges for Targeted Approaches. **2008**, 383-410
- 538 Therapeutic Counseling for the Medical Management of Renal Cell Carcinoma. **2008**, 515-534
- 537 Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. **2018**,
- 536 Molecular Imaging of Targets and Therapeutics in Tumour Angiogenesis. **2008**, 511-528
- 535 Clinical Development of the VEGFR Signalling Inhibitor AZD2171. **2008**, 673-688
- 534 Imaging the Effect of Anti-Angiogenic Tumor Therapy in Clinical Studies. **2008**, 717-739
- 533 Diseases of the Pleura and the Chest Wall. **2009**, 291-305
- 532 Mediastinum. **2008**, 281-290
- 531 Biometrie. **2006**, 215-227
- 530 Detection of disease recurrence and monitoring of therapy. **2008**, 177, 105-10
- 529 Principles of Medical Oncology. **2008**, 1-38
- 528 Allgemeine onkologische Chemotherapie. **2014**, 689-709 0
- 527 Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. **2009**, 34, 593 1
- 526 Mode of progression after radioembolization in patients with colorectal cancer liver metastases. **2020**, 10, 107 1
- 525 MANUFACTURING AND POSITIONING (GENERATIONS) OF OIL-IN-WATER NANOSIZED EMULSIONS. **2020**, 169-223

524	Active surveillance in metastatic pancreatic neuroendocrine tumors: A 20-year single-institutional experience. 2020 , 8, 3751-3762	
523	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. 2020 , 04, 373-381	
522	The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma. 2015 , 3, 305	6
521	Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases. 2014 , 26, 501-6	3
520	Experimental use of GnRH antagonists as second-line hormonal therapy. 2004 , 6 Suppl 7, S33-8	3
519	Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report. 2006 , 47, 305-9	1
518	Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic Cancer. 2004 , 4, 635-646	4
517	Biological imaging in the assessment of neoadjuvant treatment response in esophageal cancer: a new era?. 2008 , 2, 296-7	
516	The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. 2008 , 2, 287-94	14
515	LesionViewer: a tool for tracking cancer lesions over time. 2007 , 443-7	5
514	Tool support to enable evaluation of the clinical response to treatment. 2008 , 399-403	17
513	Imaging in clinical trials. 2007 , 4, 13-8	3
512	Change detection & characterization: a new tool for imaging informatics and cancer research. 2007 , 4, 1-11	1
511	Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. 2009 , 11, 43-53	72
510	Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine. 2007 , 1, 173-81	2
509	TAK1 mRNA expression in the tumor tissue of locally advanced head and neck cancer patients. 2008 , 2, 63-70	
508	Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. 2009 , 2, 289-99	20
507	Semantic reasoning with image annotations for tumor assessment. 2009 , 2009, 359-63	7

506	The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. 2008 , 8, 1	125
505	Highly malignant intra-hepatic metastatic hepatocellular carcinoma in rats. 2010 , 3, 114-20	29
504	Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. 2009 , 27,	4
503	Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients. 2010 , 2, 213-8	1
502	Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222. 2009 , 1, 61-8	2
501	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. 2007 , 2, 31-49	3
500	A semantic image annotation model to enable integrative translational research. 2009 , 2009, 106-10	7
499	Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. 2011 , 4, 2-8	10
498	Role of positron emission tomography-computed tomography in staging and early chemotherapy response evaluation in children with neuroblastoma. 2010 , 25, 147-55	5
497	The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. 2011 , 4, 444-53	34
496	Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. 2011 , 18 Suppl 2, S5-S10	10
495	Endpoints in advanced breast cancer: methodological aspects & clinical implications. 2011 , 134, 413-8	5
494	Prognostic factors of resected node-positive lung cancer: location, extent of nodal metastases, and multimodal treatment. 2011 , 8, Doc01	2
493	Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. 2011 , 4, 168-72	12
492	Recent advances in the curative treatment of colorectal liver metastases. 2011 , 4, S2-8	9
491	Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. 2011 , 4, 128-34	9
490	Clinicopathological characteristics and treatment outcomes of adult patients with paratesticular rhabdomyosarcoma (PRMS): A 10-year single-centre experience. 2012 , 6, 42-5	2
489	An approach for assessment of tumor volume from mammography in locally advanced breast cancer. 2008 , 15, 37-41	2

488	Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis. 2012 , 5, 308-14	16
487	How should we describe the benefits of palliative radiotherapy?. 2006 , 13, 230-4	3
486	A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. 2012 , 3, 90-6	15
485	A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. 2012 , 5, 77-83	12
484	(18)F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. 2011 , 1, 63-4	18
483	(18)F-FDG PET in sarcoma treatment response imaging. 2011 , 1, 47-53	30
482	PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. 2012 , 2, 458-74	39
481	Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs. 2013 , 25, 63-70	4
480	Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. 2012 , 9, 38-43	
479	Optimal chemotherapy dosing in a bilateral lower extremities amputee with metastatic pancreatic adenocarcinoma. 2013 , 6, 93-4	
478	Contrast agents for quantitative microCT of lung tumors in mice. 2013 , 63, 482-90	9
477	Clinical antiangiogenic effect of recombinant adenovirus-p53 combined with hyperthermia for advanced cancer. 2013 , 25, 749-55	5
476	Automatically pairing measured findings across narrative abdomen CT reports. 2013 , 2013, 1262-71	3
475	Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. 2012 , 37, 335-56	32
474	Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. 2014 , 4, 181-92	25
473	Clinical oncologic applications of PET/MRI: a new horizon. 2014 , 4, 202-12	53
472	Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials. 2014 , 7, 640-8	25
471	Combined chemoradiotherapy with local microwave hyperthermia for treatment of T3N0 laryngeal carcinoma: a retrospective study with long-term follow-up. 2014 , 34, 167-73	9

470	Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. 2014 , 7, 3287-92	56
469	A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 2011 , 31, 255-61	21
468	Differential protein expressions in breast cancer between drug sensitive tissues and drug resistant tissues. 2013 , 2, 62-8	5
467	Comparing docetaxel plus Cisplatin with Paclitaxel plus Carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: a single institute study. 2014 , 13, 575-81	1
466	Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery. 2014 , 6, 593-603	17
465	Stereological Evaluation of Tumor Regression Rates in Lung Cancer Using CT Via the Cavalieri Method. 2008 , 40, 109-14	1
464	Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. 2014 , 7, 3833-42	4
463	Decreased peritumoral VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. 2015 , 8, 1900-10	11
462	The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization. 2015 , 5, 220-32	4
461	Role of plasma osteopontin as a biomarker in locally advanced breast cancer. 2015 , 7, 723-32	18
460	Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence. 2015 , 28, 323-330	28
459	Laparoscopic TME associated with neoadjuvant chemoradiation towards aggressive colorectal cancer. 2015 , 8, 6032-8	
458	Prediction of radiosensitivity in primary central nervous system germ cell tumors using dynamic contrast-enhanced magnetic resonance imaging. 2015 , 27, 231-8	3
457	Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. 2015 , 12, 126-39	19
456	Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. 2015 , 8, 7728-36	13
455	The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma. 2015 , 6, 212-21	19
454	Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure. 2015 , 8, 16140-8	4
453	Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer. 2015 , 8, 13367-73	3

- 452 Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis. **2015**, 8, 18620-8
- 451 Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials. **2015**, 8, 19689-700 3
- 450 Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients. **2015**, 27, 611-26
- 449 Predictive potential role of GSTs gene polymorphisms in the treatment outcome of advanced non-small cell lung cancer patients. **2015**, 8, 20918-24 4
- 448 Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer. **2015**, 8, 22300-9 5
- 447 The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. **2016**, 4, 38
- 446 Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. **2016**, 8, 68-78 6
- 445 Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. **2012**, 74, 133-40 32
- 444 Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. **2016**, 13, 136-41 1
- 443 Plasma LUNX mRNA, a non-invasive specific biomarker for diagnosis and prognostic prediction of non-small cell lung cancer. **2016**, 6, 452-8 3
- 442 Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. **2013**, 34, 113-9 1
- 441 Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?. **2017**, 23, 183-189 4
- 440 Gamma knife stereotactic radiosurgery for renal cell carcinoma and melanoma brain metastases-comparison of dose response. **2013**, 2, 193-207 4
- 439 Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer. **2013**, 2, 243-250 1
- 438 Lung reirradiation with stereotactic body radiotherapy. **2016**, 4, 61-68 1
- 437 Initial clinical experience with stereotactic lung radiotherapy, based on a biological model-driven prescription method. **2011**, 1, 221-229
- 436 Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer. **2018**, 25, 22-31
- 435 Prospective Randomized Phase II Parallel Study of Vinorelbine Maintenance Therapy versus Best Supportive Care in Advanced Non-Small Cell Lung Cancer. **2017**, 16, 207-216 1

434	[Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors ?(2017 Edition)]. 2017 , 20, 433-445	0
433	[Quantitative Imaging Assessment of Tumor Response to Chemoradiation ?in Lung Cancer]. 2017 , 20, 407-414	1
432	[Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy]. 2011 , 14, 715-8	3
431	Pemetrexed in previously treated non-small cell lung cancer patients with poor performance status. 2011 , 14, 33-8	
430	[The clinical analysis of paclitaxel at two dose levels plus carboplatin as the first-line treatment in advanced non-small cell lung cancer]. 2011 , 14, 323-8	1
429	[First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer: ?A Network Meta-analysis]. 2016 , 19, 184-91	1
428	[A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer]. 2014 , 17, 327-35	1
427	[Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma]. 2015 , 18, 199-205	
426	[Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer]. 2013 , 16, 33-7	
425	Non Size Based Morphology Criteria for Assessment of Response in Patients with Liver Metastases of Gastrointestinal Origin Receiving Systemic Treatment. 2018 , 19, 1655-1660	
424	[Standard outcome measures for thymic malignancies]. 2014 , 17, 122-9	1
423	Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. 2019 , 9, 1235-1245	3
422	Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease. 2019 , 9, 248-254	1
421	Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers. 2019 , 18, 2163-2171	1
420	Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas. 2011 , 31, 961-6	15
419	[Breast cancer treated with primary chemotherapy: predictive factors for radical treatment (retrospective study of 72 cases)]. 2020 , 36, 174	
418	[Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. 2020 , 10, 349-374	7
417	[Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases]. 2021 , 24, 124-130	

416	Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx. 2004 , 25, 1092-8	25
415	Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?. 2005 , 26, 770-6	87
414	Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. 2021 , 13, 1568-1579	
413	Ewing sarcoma outcomes in a country with limited resources: Egypt as an example. 2021 , 11, 3212-3226	1
412	New Horizons in the Treatment of Osteosarcoma. 2021 , 385, 2066-2076	29
411	Comparison of response assessment in veterinary neuro-oncology and two volumetric neuroimaging methods to assess therapeutic brain tumour responses in veterinary patients. 2021 ,	0
410	Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials. 2021 , 1	
409	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. 2021 , 11, 772530	2
408	Association between adherence to oral therapies in cancer patients and clinical outcome: a systematic review of the literature. 2021 ,	1
407	Assessing therapy response in patient-derived xenografts. 2021 , 13, eabf4969	2
406	Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. 2021 , 8, 763271	1
405	CTKG: A Knowledge Graph for Clinical Trials.	0
404	A Nomogram Model for Predicting the Response to Transcatheter Arterial Embolization in Patients With Symptomatic Hepatic Hemangioma.. 2021 , 8, 722864	
403	Current Evidence and Directions for Intermittent Fasting During Cancer Chemotherapy. 2021 ,	2
402	A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact. 2021 , 159, 215-223	0
401	Therapie des Nierenzellkarzinoms: Das Spektrum erweitert sich.	
400	Effectiveness and Safety of Chinese Herbal Injections Combined with Fluoropyrimidine and Oxaliplatin-based Chemotherapy for Advanced Colorectal Cancer: A Systematic Review and Meta-analysis of 63 Randomized Controlled Trials. 2021 , 12, 7237-7254	0
399	Volumetric measurements of target lesions: does it improve inter-reader variability for oncological response assessment according to RECIST 1.1 guidelines compared to standard unidimensional measurements?. 2021 , 86, e594-e600	0

398	Computed Tomography Evaluation of Tumor Response in Oncology in Togo. 2021 , 12, 695-707	
397	A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis. 2021 , 4, 634	0
396	Cancer Imaging in Immunotherapy.. 2021 , 1342, 431-447	
395	Oral Chinese Patent Medicine Combined With Oxaliplatin-Based Chemotherapy Regimen for the Treatment of Colorectal Cancer: A Network Meta-Analysis. 2021 , 20, 15347354211058169	1
394	Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.. 2022 ,	0
393	Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response- Expert Panel Narrative Review.. 2022 ,	2
392	Reevaluation of statistically significant meta-analyses in advanced cancer patients using the Hartung-Knapp method and prediction intervals - a methodological study.. 2021 ,	0
391	Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.. 2021 , 11, 800547	0
390	Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients.. 2021 , 7, 100366	1
389	Docetaxel y gemcitabina en el tratamiento del carcinoma de pñreas metastñico. 2002 , 4, 72-76	
388	Relationship between serum survivin levels before radiotherapy and clinical response in patient with stage iib cervical carcinoma. 2020 , 11,	
387	Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.. 2021 , 14, 17562848211066206	0
386	Intraperitoneal Paclitaxel Combined with S-1 Plus Oxaliplatin for Advanced Gastric Cancer with Peritoneal Metastasis: a Phase I Study.. 2021 , 21, 418-425	0
385	Introduction of R-MPV Therapy for Primary Central Nervous System Lymphoma:A Report of Our Experience. 2021 , 80, 225-231	
384	Early detection of treatment futility in patients with metastatic colorectal cancer.. 2022 , 13, 61-72	0
383	The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.. 2022 , 1, CD013345	2
382	Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence.. 2021 ,	0
381	Metastatic uveal melanoma: The final frontier.. 2022 , 101041	3

380	Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer.. 2022 , 14,	
379	Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).. 2022 , 27, 251-e304	
378	Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection.. 2022 , 1	1
377	Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy.. 2022 , 10, 899-918	0
376	Independent Drug Action in Combination Therapy: Implications for Precision Oncology.. 2022 ,	5
375	Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC.. 2022 , 14,	0
374	Response Evaluation Criteria in Cancer of the Liver version 6 (RECICL 2021 Revised Version).. 2022 ,	2
373	Intérêt pronostique et prédictif de la TEP-TDM au 18F-FDG chez les patients atteints de l'omyosarcomes de stades avancés. 2022 , 46, 14-22	
372	Stereotactic Radiation and Dual Human Epidermal Growth Factor Receptor 2 Blockade with Trastuzumab and Pertuzumab in the Treatment of Breast Cancer Brain Metastases: A Single Institution Series.. 2022 , 14,	0
371	Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.. 2021 ,	0
370	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma.. 2022 ,	0
369	Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.. 2022 , 22, 94	0
368	WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.. 2022 , 23, 65	0
367	Radiological progression of extremity soft tissue sarcoma following pre-operative radiotherapy predicts for poor survival. 2021 , 20210936	
366	Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors.. 2022 , 14,	3
365	Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.. 2021 , 165, 10-17	
364	Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.. 2022 , 14, 17588359211058391	
363	Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.. 2022 , 41, 50	1

362	A randomized phase-II study of reirradiation and hyperthermia versus reirradiation and hyperthermia plus chemotherapy for locally recurrent breast cancer in previously irradiated area.. 2022 , 1-8	0
361	Circulating tumor cells may serve as a supplement to RECIST in neoadjuvant chemotherapy of patients with locally advanced breast cancer.. 2022 , 1	0
360	Classical mathematical models for prediction of response to chemotherapy and immunotherapy.. 2022 , 18, e1009822	1
359	MRI for in vivo Analysis of Ablation Zones Formed by Cooled Radiofrequency Neurotomy to Treat Chronic Joint Pain Across Multiple Axial Spine Sites.. 2022 , 15, 423-430	0
358	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.. 2021 , 13,	0
357	Methoden klinischer Prüfung in der Onkologie. 2021 , 1-53	
356	Comparison of UGT1A1 polymorphism as guidance of irinotecan dose escalation in RAS wild type metastatic colorectal cancer patients treated with cetuximab or bevacizumab plus FOLFIRI as the first-line therapy.. 2022 ,	1
355	Electrochemotherapy vs radiotherapy in the treatment of primary cutaneous malignancies or cutaneous metastases from primary solid organ malignancies: a protocol for a systematic review and meta-analysis. 2022 , 2022,	
354	Comparing Deep Learning and Conventional Machine Learning for Outcome Prediction of Head and Neck Cancer in PET/CT. 2022 , 318-326	
353	AIM and Brain Tumors. 2022 , 1717-1732	
352	Safety and effectiveness of gemcitabine for the treatment of classic Kaposi's sarcoma without visceral involvement.. 2022 , 14, 17588359221086829	
351	Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring Rearrangement: A Case Report.. 2022 , 12, 761558	1
350	The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study.. 2022 , 9, 856064	2
349	The Systemic Immune-Inflammation Index is an Independent Predictor of Survival in Breast Cancer Patients.. 2022 , 14, 775-820	2
348	Bayesian two-stage design for phase II oncology trials with binary endpoint.. 2022 ,	
347	Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis.. 2022 , 12, 827777	0
346	A Phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors.. 2022 ,	2
345	A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer.. 2022 , 12,	0

- 344 The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis.. **2022**, 22, 216
- 343 Local tumour response to neoadjuvant therapy with 2-aminoethyl dihydrogen phosphate in dogs with soft tissue sarcoma.. **2022**, ○
- 342 Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.. **2022**, 22, 342
- 341 A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.. **2022**, 1
- 340 Electrochemotherapy Is Effective in the Treatment of Bone Metastases.. **2022**, 29, 1672-1682 ○
- 339 Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma.. **2022**, 6, e2100335 1
- 338 Outcomes of proton therapy for non-small cell lung cancer in patients with interstitial pneumonia.. **2022**, 17, 56 1
- 337 Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (-TKI) in -Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.. **2022**, 14, 863-873 ○
- 336 The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.. **2022**, 4, vdac032
- 335 The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review.. **2022**, 1 1
- 334 Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinoradiological response outcomes.. **2022**, 1
- 333 A knowledge graph of clinical trials ([Formula: see text]).. **2022**, 12, 4724 ○
- 332 Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization using Drug-Eluting Beads.. **2022**,
- 331 Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.. **2022**, 1 4
- 330 Surgical Efficacy and Safety of Patients with Locally Advanced Gastric Cancer following Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy.. **2022**, 2022, 3719241 ○
- 329 Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study.. **2022**, 14, 1259-1266 ○
- 328 Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.. **2022**, 14, ○
- 327 Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy.. **2022**, 17, e0266001 ○

326	Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma.. 2022,	0
325	Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials.. 2022,	
324	Definition of Castrate Resistant Prostate Cancer: New Insights.. 2022, 10,	3
323	Prognostic impact of inter-metastatic heterogeneity of viable tumour cells in colorectal liver metastases.. 2022,	
322	Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas.. 2022, 14,	0
321	Procarbazine, prednisolone and cyclophosphamide (PPC) oral combination chemotherapy protocol for canine lymphoma.. 2022,	
320	Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.. 2022,	0
319	Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone.. 2022, 12,	0
318	Prospective cohort study by InspECT on safety and efficacy of electrochemotherapy for cutaneous tumors and metastases depending on ulceration.. 2022,	
317	Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry.. 2022,	1
316	Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) - A systematic review.. 2022, 172, 103650	0
315	Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.. 2022,	0
314	The Role and Potential of F-FDG PET/CT in Malignant Melanoma: Prognostication, Monitoring Response to Targeted and Immunotherapy, and Radiomics.. 2022, 12,	0
313	FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.. 2022, 165, 48-57	0
312	Interobserver and intraobserver variability of RECIST assessment in ovarian cancer.. 2022,	0
311	Robustness and reproducibility of radiomics in T2 weighted images from magnetic resonance image guided linear accelerator in a phantom study.. 2022, 96, 130-139	1
310	Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards.. 2022, 41, 1059-1065	2
309	Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial.. 2022, 34, 15-22	2

308	Deep learning for locally advanced nasopharyngeal carcinoma prognostication based on pre- and post-treatment MRI.. 2022 , 219, 106785	1
307	Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning. 2021 , 118,	1
306	Role of tumour- associated neutrophils in tissue material and systemic neutrophil inflammation in colorectal cancer patients. 2021 , 11, 85-98	
305	tRNA-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression.. 2021 , 14,	2
304	Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.. 2021 , 12,	1
303	Proposing Response Evaluation Criteria in Solid Tumors Based on Genomic Profiling or Genomic RECIST: A Retrospective Study on the Liquid Biopsy Results of 29 Cancer Patients.	
302	Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. 2021 ,	0
301	Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.. 2021 , 28, 5179-5191	1
300	Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.. 2021 , 11, 764189	3
299	MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts.. 2021 , 1-9	1
298	Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.. 2021 , 192, 131	0
297	Perioperative and long-term outcome of en-bloc arterial resection in pancreatic surgery.. 2021 ,	
296	Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.. 2021 , 21, 1344	2
295	Multi-context 3D Resnet for Small-size False Positive Reduction in Pelvic Lymph Node Detection. 2021 ,	
294	BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in -Mutated Metastatic Colorectal Cancer-A Case Series Study BRAF-.. 2021 , 57,	2
293	Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version). 2021 , 62, 823-829	
292	Neoadjuvant treatment strategies for hepatocellular carcinoma.. 2021 , 13, 1550-1566	2
291	Bone Metastasis of Non-Small-Cell Lung Cancer Showing Pathological Complete Response to Osimertinib Monotherapy.. 2021 , 14, 1876-1881	

290	Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. 2021 , 12, CD011300	1
289	Changes in muscle measures during chemoradiotherapy in patients with limited stage small cell lung cancer. 2021 , 6, 24-32	
288	Sodium Tetradecyl Sulphate Sclerotherapy for Lateral Malleolar Bursitis of the Ankle. 14,	
287	Diagnostic Applications of Nuclear Medicine: Tumors of the Liver and Biliary Tract. 2022 , 1-26	
286	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.. 2022 , 89, 721	0
285	Progress in neoadjuvant therapy for gastric cancer.. 2022 , 23, 172	0
284	Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12C.. 2022 ,	4
283	Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.. 2022 , 100710	0
282	Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: Real-world outcomes in a multicenter retrospective cohort study.. 2022 ,	0
281	Efficacy of non-platinum chemotherapy in platinum-resistant ovarian cancer: a meta-analysis. 2022 , 12, 21-35	
280	I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis.. 2022 , 17, 75	2
279	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and F-FDG Metabolic Activity in Non-Small Cell Lung Cancer.. 2022 , 12, 780186	1
278	Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.. 2022 , 22, 407	0
277	A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies.. 2022 ,	1
276	Mapping Cancer Registry Data to the Episode Domain of the Observational Medical Outcomes Partnership Model (OMOP). 2022 , 12, 4010	
275	Novel developments in MR assessment of treatment response after locoregional therapy. 77-84	
274	DataSheet_1.doc. 2019 ,	
273	Table_1.docx. 2018 ,	

272 Table_1.docx. **2020**,

271 Table_2.docx. **2020**,

270 Image_1.tif. **2021**,

269 Table_1.docx. **2021**,

268 Table_1.docx. **2020**,

267 Table_2.docx. **2020**,

266 Table_1.DOC. **2018**,

265 Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer.. **2022**, ○

264 Prospektive Kohortenstudie von InspECT zur Sicherheit und Wirksamkeit der Elektrochemotherapie bei Hauttumoren und Metastasen in Abhängigkeit von Ulzeration.. **2022**, 20, 470-482

263 Predictive significance of inflammatory indexes in metastatic nonsmall cell lung cancer patients treated with platinum-doublet chemotherapy.. **2022**, 18, 220-223 ○

262 Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?. **2017**, 23, 183 3

261 The longitudinal change of circulating tumor cell during chemotherapy and its correlation with disease features, treatment response and survival profile of advanced gallbladder carcinoma.. **2021**, 13, 13590-13598

260 Diagnostic Applications of Nuclear Medicine: Pediatric Cancers. **2022**, 1-37

259 Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only.. **2022**, 14, 1541-1549 ○

258 Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.. **2022**, 15, 437-468 1

257 Deciphering radiological stable disease to immune checkpoint inhibitors.. **2022**, ○

256 Post-Radiotherapy PET Image Outcome Prediction by Deep Learning Under Biological Model Guidance: A Feasibility Study of Oropharyngeal Cancer Application. **2022**, 12, ○

255 Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. **2022**, 28, 1768-1780 ○

- 254 Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non-small cell lung cancer trials using real-world data.. **2022,** 2
- 253 Predictive value of clinical and F-FDG-PET/CT derived imaging parameters in patients undergoing neoadjuvant chemoradiation for esophageal squamous cell carcinoma.. **2022,** 12, 7148
- 252 Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy.. **2022,**
- 251 Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer.. **2022,** 0
- 250 Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.. **2022,** 0
- 249 F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial.. **2022,** 1 0
- 248 Detection of Specific Immune Cell Subpopulation Changes Associated with Systemic Immune Inflammation Index Level in Germ Cell Tumors. **2022,** 12, 678
- 247 Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.. **2022,** 108, 108803 0
- 246 Early assessment of chemotherapeutic response in hepatocellular carcinoma based on serum surface-enhanced Raman spectroscopy.. **2022,** 278, 121314 0
- 245 First-line chemotherapy in advanced intrabdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.. **2022,** 0
- 244 Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse.. **2022,** 169, 179-187 0
- 243 CPI Adult Cancer Imaging Special Edition Module. **2019,**
- 242 Monitoring Gastrointestinal Tumor Response to Therapy. **2015,** 2295-2305
- 241 A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. **2005,** 11, 284-289 10
- 240 Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. **2022,** 13, 1
- 239 A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.. **2022,** 12, 1648-1659
- 238 Non-Invasive Characterization of Experimental Bone Metastasis in Obesity Using Multiparametric MRI and PET/CT. **2022,** 14, 2482
- 237 A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. **2022,** 39,

- 236 Long-Term Outcomes in Head and Neck Paragangliomas Managed with Intensity-Modulated Radiotherapy. 1
- 235 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. **2022**, 10, e003956 0
- 234 Four-Dimensional Machine Learning Radiomics for the Pretreatment Assessment of Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy in Dynamic Contrast-Enhanced MRI. 0
- 233 FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. **2022**, 0
- 232 Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set. **2022**, 14, 2625
- 231 Plasma profile of immune determinants predicts pathological complete response in locally advanced breast cancer patients: a pilot study. **2022**,
- 230 Complete Response After Pre-Operative Transcatheter Arterial Chemoembolization for Unresectable Primary Hepatic Neuroendocrine Tumour: A Case Report and Literature Review. 12,
- 229 Association of CT-Based Delta Radiomics Biomarker With Progression-Free Survival in Patients With Colorectal Liver Metastases Undergo Chemotherapy. 12, 1
- 228 Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression. Volume 14, 1891-1902
- 227 New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. **2022**, 10, 885 0
- 226 Single material beam hardening correction via an analytical energy response model for diagnostic CT. 0
- 225 Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. **2022**, 170, 196-208 1
- 224 Imaging response assessment for oncology: An algorithmic approach. **2022**, 9, 100426 0
- 223 Diagnostic Applications of Nuclear Medicine: Tumors of the Liver and Biliary Tract. **2022**, 1-26
- 222 Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. **2022**, 10, e004495 2
- 221 Authors[Reply to Preventing Futile Liver Resection: Biology Should be Central in Patients] Selection.
- 220 Evaluation of cancer outcome assessment using MRI: A review of deep learning methods.
- 219 Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab. **2022**, 14, 3054

218 Assessing the performance of different outcomes for tumor growth studies with animal models.

217 A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. Publish Ahead of Print,

216 A homogeneous treatment for non-DIPG diffuse midline glioma. 030089162210990

215 Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. **2022**, 10, e004509

214 Myeloid-derived suppressor cell dynamics control outcomes in the metastatic niche.

213 Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study.

212 iRECIST and atypical patterns of response to immuno-oncology drugs. **2022**, 10, e004849

211 A Phase I Study of Apolizumab, an Anti-HLA-DR Echain Monoclonal Antibody, in Patients With Solid Tumor Malignancies. **2022**, 45, 294-297

210 Metastatic rhabdomyosarcoma: evidence of the impact of radiotherapy on survival. A retrospective single-center experience.

209 Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.

208 Precision Medicine in Solid Tumors: How Far We Traveled So Far?. **2022**, 14, 3202

207 Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT. **2022**, 10, 1-114

206 Clinical Experience on Use of Oral EGFR-TKIs as First-line Treatment of Advanced NSCLC from a Tertiary Care Centre in North India and Implications of Skin Rash. **2022**, 56, 149-152

205 Application of Dynamic 18F-FDG PET/CT for Distinguishing Intrapulmonary Metastases from Synchronous Multiple Primary Lung Cancer. **2022**, 2022, 1-18

204 Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.

203 Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series. **2022**, 50, 030006052211106

202 Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression. **2022**, 22,

201 Statistical handling of death events in the analysis of time to progression: A review of oncology journals. **2022**, 106858

200	Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response. 2022 ,	
199	Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. 2022 , 13,	0
198	Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.	1
197	Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC.	0
196	Optimal single-arm two-stage designs with consideration of dependency on efficacy and safety. 096228022211115	
195	Dehydroepiandrosterone (DHEA) Sensitizes Irinotecan to Suppress Head and Neck Cancer Stem-Like Cells by Downregulation of WNT Signaling. 12,	
194	Tumor growth towards lower extracellular matrix conductivity regions under Darcy's Law and steady morphology. 2022 , 85,	
193	A Phase I Trial and Pharmacokinetic Study of Tipifarnib, a Farnesyltransferase Inhibitor, and Tamoxifen in Metastatic Breast Cancer. 2005 , 11, 1247-1252	8
192	UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan. 2005 , 11, 1226-1236	41
191	Assessing Response to Therapy. 2023 , 28-38	
190	A Multidisciplinary Approach to Cancer: A Radiologist's View. 2023 , 1-6	
189	A Multidisciplinary Approach to Cancer: A Surgeon's View. 2023 , 7-13	
188	Cancer-Related Anorexia/Cachexia Syndrome and Oxidative Stress: An Innovative Approach beyond Current Treatment. 2004 , 13, 1651-1659	16
187	THREE-DIMENSIONAL VOLUMETRICS FOR TRACKING VESTIBULAR SCHWANNOMA GROWTH IN NEUROFIBROMATOSIS TYPE II. 2008 , 62, 1314-1320	5
186	A phase I/II study of triple-mutated oncolytic herpes virus G47 Δ in patients with progressive glioblastoma. 2022 , 13,	5
185	Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers. 12,	0
184	Metronomic chemotherapy in patients with advanced neuroendocrine tumors: a single-center retrospective analysis.	
183	Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX. 12,	

182	Editorial: Response assessment of radioligand therapies. 12,	0
181	Myeloid-Derived Suppressor Cells and CD68+CD163+M2-Like Macrophages as Therapeutic Response Biomarkers Are Associated with Plasma Inflammatory Cytokines: A Preliminary Study for Non-Small Cell Lung Cancer Patients in Radiotherapy. 2022 , 2022, 1-16	0
180	Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials. 2022 , 173, 167-177	0
179	Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced NonSmall Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial. 2005 , 11, 690-696	24
178	Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors. 2005 , 11, 703-711	12
177	Assessment of Early Response to Lung Cancer Chemotherapy by Semiquantitative Analysis of Dynamic Contrast-Enhanced MRI. 2022 , 2022, 1-7	
176	Frailty and clinical outcomes in critically ill patients with cancer: A cohort study. 2022 ,	0
175	Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.	1
174	Radiosurgery and Stereotactic Brain Radiotherapy with Systemic Therapy in Recurrent High-Grade Gliomas: Is It Feasible? Therapeutic Strategies in Recurrent High-Grade Gliomas. 2022 , 12, 1336	0
173	Surgical and Oncological Outcomes after Neoadjuvant Therapy for Non-Metastatic Gastric GISTs.	
172	The effect of intrathoracic lesion location on initial tyrosine kinase inhibitor response in advanced oncogene-addicted non-small cell lung cancer: A comparison between RECIST 1.1 and a novel method of response assessment (MAX).. 2022 ,	
171	The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022 , 29, 6137-6153	2
170	Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. 2022 , 14,	0
169	A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma. 2022 , 21,	0
168	A Single-Arm Confirmatory Study of Definitive Chemoradiotherapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). 2022 ,	1
167	Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer. 2022 ,	0
166	Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.	
165	First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.	1

- 164 Placebo effect in the treatment of non-small cell lung cancer: a meta-analysis. Publish Ahead of Print,
- 163 Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/ SWOG 80405.
- 162 Successful treatment of advanced muscle-invasive bladder cancer with the combined therapy of toripalimab and chemotherapy: a case report. Publish Ahead of Print,
- 161 Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis. ○
- 160 Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. Volume 9, 1011-1027 ○
- 159 First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinoma in routine clinical practice-results from A Subgroup Analysis. ○
- 158 Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival. **2022**, 175, 274-281 ○
- 157 A literature review and database of how the primary KIT/PDGFR α variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib. **2022**, 268-269, 46-54 ○
- 156 Quantitative In Vivo Imaging to Enable Tumour Forecasting and Treatment Optimization. **2022**, 55-97 1
- 155 Diagnostic Applications of Nuclear Medicine: Tumors of the Liver and Biliary Tract. **2022**, 865-890 ○
- 154 Assessment of Tumour Response to Neoadjuvant Therapy for the Treatment of Oesophageal Cancer. **2022**, 147-162 ○
- 153 Diagnostic Applications of Nuclear Medicine: Gastrointestinal Stromal Tumors. **2022**, 847-864 ○
- 152 Diagnostic Applications of Nuclear Medicine: Pediatric Cancers. **2022**, 1271-1307 ○
- 151 Quantitative DCE-MRI of the Breast. **2022**, 425-458 ○
- 150 Diagnostic Applications of Nuclear Medicine: Gastrointestinal Stromal Tumors. **2022**, 1-19 ○
- 149 Neuroimaging issues in assessing glioma response to brain tumour therapy. **2022**, 809-819 ○
- 148 Pseudo-progression in neuro-oncology. **2022**, 821-839 ○
- 147 Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials. 12, ○

146	Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review. 13,	1
145	Construction and Validation of an Oxaliplatin-Resistant Gene Signature in Colorectal Cancer Patients Who Underwent Chemotherapy. 2022 , 15, 1139	0
144	Prognostic impact of conversion hepatectomy for initially unresectable colorectal liver metastasis.	0
143	Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.	0
142	Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi-institutional propensity-matched cohort study.	0
141	The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian CancerHyperthermia versus Normothermia: A Randomized Controlled Trial. 2022 , 11, 5785	0
140	Results of salvage treatment with CyberKnife [®] fractionated radiosurgery in recurrent large chordoma.	0
139	High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. 2022 , 13,	2
138	Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer. 12,	0
137	HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients. 2022 ,	0
136	Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. 2022 , 7,	0
135	Circadian as a prognostic factor for radiation responses in patients with cervical cancer: A nested case-control study. 2022 , 48,	0
134	Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. 2022 , 14, 4340	0
133	Change of tumor-infiltrating lymphocyte of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma. 14, 1008-1025	0
132	Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer. 2022 , 24,	0
131	Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists. 2022 , 42, 1670-1689	1
130	Role of palliative chemoradiation in locally advanced head and neck cancer: A case series done in a tertiary care center in Uttar Pradesh. 2021 , 1, 98	0
129	Robotic stereotactic body radiotherapy for recurrent nasopharyngeal carcinoma. 2022 , 0	0

128	Neoadjuvant intra-arterial chemotherapy to avoid reconstructive surgery for oral cancer patients aged 80 years. 2022 , 30, 115-120	0
127	Shear Wave Elastography Combined with Molecular Subtype in Early Prediction of Pathological Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Prospective Study. 2022 , 14, 5068	0
126	Development of a ClinicalBiological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial. 2022 , 14, 5068	0
125	Chinese patent medicine Kanglaite injection for non-small-cell lung cancer: An overview of systematic reviews. 2022 , 115814	1
124	Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables.	1
123	From Nuclear Reactor-Based to Proton Accelerator-Based Therapy: The Finnish Boron Neutron Capture Therapy Experience.	3
122	A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. 2022 ,	0
121	Estimating the optimal linear combination of predictors using spherically constrained optimization. 2022 , 23,	0
120	Short-term outcomes of chemoradiotherapy and local excision vs total mesorectal excision in T2-3ab,N0,M0 rectal cancer. A multicentre randomised, controlled, phase III trial (the TAUTEM study).. 2022 ,	0
119	Metallo-Drugs in Cancer Therapy: Past, Present and Future. 2022 , 27, 6485	7
118	Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. 2022 , 22,	0
117	Outcomes and Imaging Analysis in Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. 2022 ,	0
116	Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma. 12,	0
115	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study. 2022 , 101, e30871	0
114	Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.	0
113	Editorial. Assessing treatment response following stereotactic body radiotherapy for spinal metastases. 2022 , 53, E11	0
112	Intratumoral injection of holmium-166 microspheres as neoadjuvant therapy of soft tissue sarcomas in dogs. 9,	0
111	Molecular hallmarks of cancer. 2023 , 489-505.e5	0

110	A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.	0
109	Empowering drug development: leveraging insights from imaging technologies to enable the advancement of digital health technologies.	0
108	A Framework for Harmonization of Radiomics Data for Multicenter Studies and Clinical Trials. 2022,	1
107	Palliative repeated electroporations of oral tumours in dogs: A case series. 9,	0
106	Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis. 12,	0
105	Diagnostic impact of CEA and CA 15-3 on monitoring chemotherapy of breast cancer patients. 11, 57-63	1
104	Short-term efficacy and long-term survival of nasopharyngeal carcinoma patients with radiographically visible residual disease following observation or additional intervention: A real-world study in China.	0
103	Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy for Lung Cancer. 2022,	0
102	A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. 34,	0
101	Innovative Imaging Techniques Used to Evaluate Borderline-Resectable Pancreatic Adenocarcinoma. 2023, 284, 42-53	0
100	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2022, 23, 1126	4
99	Imaging Response Evaluation. 2022, 417-439	0
98	Combined treatment of rectal cancer with moderate risk of tumor progression. 2022, 36	0
97	Relapse after non-metastatic rhabdomyosarcoma: The impact of routine surveillance imaging on early detection and post-relapse survival. 2023, 70,	0
96	Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma. 2022, 14, 5676	0
95	The clinical experience of the prognosis in opposite CEA and image change after therapy in stage IV colorectal cancer. 2022, 12,	0
94	Role of Post-Treatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients Receiving Definitive Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinomas. 2022, 65, 697-704	0
93	ATR Inhibitors in Platinum-Resistant Ovarian Cancer. 2022, 14, 5902	1

- 92 Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. **2022**, 2022, 0
- 91 Imaging endpoints for clinical trial use: a RECIST perspective. **2022**, 10, e005092 0
- 90 Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. 0
- 89 Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group (iMig). **2022**, 0
- 88 Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. **2022**, 2022, 0
- 87 Dual-energy CT iodine map in predicting the efficacy of neoadjuvant chemotherapy for hypopharyngeal carcinoma: a preliminary study. **2022**, 12, 0
- 86 Leberteilresektionen bei Lebermetastasen Neue translationale Konzepte. 0
- 85 AAPM task group report 273: Recommendations on best practices for ai and machine learning for computer-aided diagnosis in medical imaging. 1
- 84 Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. 0
- 83 Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation. **2022**, 22, 0
- 82 Biomarker response to high-specific-activity I-131 MIBG in pheochromocytoma/paraganglioma. **2022**, 0
- 81 Muscle mass loss in breast cancer patients of reproductive age (15 years) undergoing neoadjuvant chemotherapy. 1
- 80 HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response. 0
- 79 Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study. ijgc-2022-003764 0
- 78 External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. 0
- 77 Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy. **2022**, 30, 65-76 0
- 76 Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. **2023**, 100929 0
- 75 Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study. **2023**, 15, 434 0

- 74 Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. ○
- 73 Interdisziplinäre Besprechungen. ○
- 72 Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma. **2023**, 15, 412 ○
- 71 Radiological response criteria in non-small cell lung cancer treated with immunotherapy: RECIST1.1 vs. iRECIST. **2023**, 9, ○
- 70 Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. **2023**, 11, ○
- 69 Thymidine Kinase Activity Levels in Serum Can Identify HR + Metastatic Breast Cancer Patients with a Low Risk of Early Progression (SWOG S0226). 1-15 ○
- 68 Multistate pharmacometric model to define the impact of second-line immuno-therapies on the survival outcome of IMpower131 study. ○
- 67 Risk model and factors for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer-a two-center cohort study. **2023**, 23, ○
- 66 Prostate Cancer Tumor Volume and Genomic Risk. **2023**, 48, 90-97 ○
- 65 Machine learning-based models for genomic predicting neoadjuvant chemotherapeutic sensitivity in cervical cancer. **2023**, 159, 114256 1
- 64 Bilateral Synchronous Locally Advanced Carcinoma of the Breast in a Woman Over 100 Years Old. **2022**, 83, 1-3 ○
- 63 The Applications of Artificial Intelligence in Digestive System Neoplasms: A Review. ○
- 62 Prinzipien der nicht-chirurgischen lokoregionären Therapie. **2023**, 1-10 ○
- 61 Treatment outcomes of alternating chemoradiotherapy for nasopharyngeal carcinoma: a single-center safety and efficacy study. **2022**, ○
- 60 Grundlagen der medikamentösen Tumorthherapie. **2022**, 1-23 ○
- 59 Predicting Soft Tissue Sarcoma Response to Neoadjuvant Chemotherapy Using an MRI-Based Delta-Radiomics Approach. ○
- 58 Computational imaging applications in brain and breast cancer. **2023**, 29-45 ○
- 57 Anti-TIF1 antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review. ○

- 56 MRI of mesorectum and rectal cancer staging. **2023**, 1-30 ○
- 55 High Intensity Focused Ultrasound Ablation for Patients With Locally Advanced Pancreatic Adenocarcinoma. ○
- 54 Efficacy of third-generation EGFR-TKIs in advanced NSCLC with different T790M statuses tested via ddPCR and NGS. ○
- 53 Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial. **2023**, 13, e062659 ○
- 52 Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma. **2023**, 22, 209-220 ○
- 51 18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer. **2023**, 54, ○
- 50 Predictive power of deep-learning segmentation based prognostication model in non-small cell lung cancer. 13, ○
- 49 Pancreatic intra-arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma: A pilot study. **2022**, 18, 1945 ○
- 48 Intra- and peritumoral MRI radiomics assisted in predicting radiochemotherapy response in metastatic cervical lymph nodes of nasopharyngeal cancer. ○
- 47 Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. **2023**, 24, 3151 1
- 46 Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study. **2023**, 102, e32866 ○
- 45 Pediatric Rhabdomyosarcoma Protocols Should Include More Detailed Imaging Guidelines to Ensure Homogeneous Response Assessment. ○
- 44 Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial. **2023**, 181, 109505 ○
- 43 Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. ○
- 42 Colonoscopy, imaging, and carcinoembryonic antigen: Comparison of guideline adherence to surveillance strategies in patients who underwent resection of colorectal cancer - A systematic review and meta-analysis. **2023**, 47, 101910 ○
- 41 The predictive value of plasma exosomal lncRNAs/mRNAs in NSCLC patients receiving immunotherapy. **2023**, 68, 86-93 ○
- 40 Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma. 14, ○
- 39 Drug-eluting beads loaded with irinotecan to treat synchronous liver-only metastases of colorectal cancer non-responsive to bevacizumab-based chemotherapy. ○

- 38 The auxiliary effects of low-molecular-weight fucoidan on the quality of life for locally advanced rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy before surgery: A double-blind, randomized, placebo- controlled study. ○
- 37 CT-based radiomics for the identification of colorectal cancer liver metastases sensitive to first-line irinotecan-based chemotherapy. ○
- 36 Myeloid-Derived Suppressor Cell Dynamics Control Outcomes in the Metastatic Niche. OF1-OF15 ○
- 35 Diagnostic Performance of Response Assessment FDG-PET/CECT in HNSCC Treated With Definitive Radio(chemo)therapy Using NI-RADS. ○
- 34 Imaging recommendations for the management of pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Consensus statement of the International Soft Tissue Sarcoma Consortium (INSTRuCT). **2023**, 1, 100008 ○
- 33 How Do Cancer-Specific Computed Tomography Protocols Compare With the American College of Radiology Dose Index Registry? An Analysis of Computed Tomography Dose at 2 Cancer Centers. Publish Ahead of Print, ○
- 32 Multisystem Imaging Recommendations/Guidelines: In the Pursuit of Precision Oncology. **2023**, 44, 002-025 ○
- 31 Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. 14, ○
- 30 KDM5D Histone Demethylase Identifies Platinum-Tolerant Head and Neck Cancer Cells Vulnerable to Mitotic Catastrophe. **2023**, 24, 5310 ○
- 29 Thoracic Malignancies. **2023**, 333-350 ○
- 28 Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment. **2023**, 15, 1751 ○
- 27 Breast cancer immunotherapy and personalized medicine. 146-158 ○
- 26 Predicting the efficacy of radiotherapy for esophageal squamous cell carcinoma based on enhanced computed tomography radiomics and combined models. 13, ○
- 25 Imaging Features of Immunotherapy. **2023**, 169-176 ○
- 24 Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy. 29, 1669-1684 ○
- 23 PD-L1 expression in anaplastic thyroid carcinoma treated with lenvatinib. ○
- 22 Is the association of electrochemotherapy and bone fixation rational in patients with bone metastasis?. ○
- 21 Molecular imaging for cancer immunotherapy. **2023**, 1, 3-17 ○

- 20 Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 (Oligometastatic) and M2 (Polymetastatic) subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC). 13, ○
- 19 How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?. 13, ○
- 18 Efficacy of concurrent radiotherapy in patients with locally advanced rectal cancer and synchronous metastasis receiving systemic therapy. 13, ○
- 17 Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer. ○
- 16 Treatment outcomes of extraskeletal Ewing sarcoma. ○
- 15 Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment. ○
- 14 Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in lung squamous cell carcinoma patients underwent conventional chemoradiotherapy. 2023, 18, ○
- 13 Estimating optimal individualized treatment rules with multistate processes. ○
- 12 Automatic Enlarged Lymph Node Detection by Volume Estimation from 3D Abdominal CT Images Based on Speed Up Robust Features and Maximum Intensity Projection. 2023, ○
- 11 Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: AJR Expert Panel Narrative Review. ○
- 10 Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. 2023, 11, e005828 ○
- 9 Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study. 2023, 15, 2188 ○
- 8 Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma. 2023, ○
- 7 Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort. 2023, 23, ○
- 6 Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China. 2023, 102, e33434 ○
- 5 Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma. 13, ○
- 4 Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis. ○
- 3 Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group. ○

- 2 Adult T-cell leukemia and lymphoma in French Guiana: a retrospective analysis with real-life data from 2009 to 2019. **2023**, 21, 100492 ○
- 1 Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. ○